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Certain HLA-B-restricted CD8+ T cell responses are associated with control of viremia 
whereas HLA-Cw* restricted responses, including Gag epitopes are associated with high 
viremia.  To better understand the role of HLA-Cw* restricted epitopes in viral control, 
HLA-Cw* restricted epitopes were optimally defined. Seventy eight study subjects from 
a cohort of 451 chronically infected participants had HLA-Cw* restricted CD8+ T cells 
responses as quantified by intracellular cytokine staining assessing IFN-γ secretion. Fine 
mapping and HLA restriction of the optimally defined HLA-Cw* restricted epitopes were 
performed using ELISPOT assay.  Functional avidity of responses was assessed by 
peptide dilution in an ELISPOT assay. Two novel HLA-Cw* restricted epitopes Cw*04-
TF10 (in reverse transcriptase) and Cw*08-RM9 (in gp120) were optimally defined.  A 
previously described epitope, Cw*07- KY11 (Nef) was the most frequently targeted 
epitope in this cohort (30/78) and has high functional avidity compared to other HLA-Cw 
restricted CD8+ T cell responses.  
 
The polyfunctionality of HLA-B*57/5801-restricted Gag-specific HIV-1 CD8+ T cell 
responses and HLA-Cw*07-KY11 restricted CD8+ T cell responses within the same 
study subject was determined. Polyfunctionality of CD8+ T cell responses to HLA-
B*57/5801 and HLA-Cw*07 restricted epitopes were determined in nine study subjects 
assessing IFN-γ, TNF-α, IL-2, MIP-1β, and CD107a by multicolour flow cytometry. 
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Additionally gag and nef genes were sequenced from plasma. HLA-B*57/5801-restricted 
IFN-γ-producing CD8+ T cell responses were of lower magnitude than HLA-Cw*07 
responses (p=0.0012) for the nine subjects. The majority of responses were 
monofunctional (75%), irrespective of HLA restriction. HLA-B*57/5801 and HLA-
Cw*07 restricted CD8+ T cells did not differ significantly in polyfunctionality (p=0.84). 
Possession of ≥3 functions correlated positively with CD4+ T cell counts (r=0.85; 
p=0.006). The percentages of monofunctional CD8+ T cells inversely correlated with 
CD4+ T cell counts (r=-0.79; p=0.05). There was no correlation between 
polyfunctionality and viral load and sequence variation within targeted epitopes did not 
impact polyfunctionality. These results suggest that polyfunctionality of HIV-1-specific 
CD8+ T cells is associated with disease progression independent of restricting HLA 
alleles, and that loss of these polyfunctional cells correlates with increased in the 
frequency of monofunctional virus-specific CD8+ T cells. In addition, sequence variation 
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CHAPTER 1. INTRODUCTION 
1.1. HIV AND IMMUNE SYSTEM 
 
The human immunodeficiency virus (HIV) is the causative agent for the most destructive 
pandemic worldwide since it was first reported in 1981. There are about 33.4 million 
reported cases of people living with HIV infection worldwide and 22.4 million live in 
sub-Saharan Africa (UNAIDS, 2009). South Africa has the highest rate of HIV infection 
in the world with the province of KwaZulu-Natal leading the HIV prevalence in South 
Africa. Currently, there is no cure for HIV or an effective vaccine (Hahn et al., 2000, 
Goulder and Watkins, 2008).  However, the introduction of highly active antiretroviral 
therapy (HAART) has transformed the management of HIV in developed countries. The 
increasing number of new HIV infections, indicate the need to develop an effective 
vaccine to protect against HIV infection. Traditional vaccine strategies have so far failed 
to protect against HIV infection with a high degree of efficacy (Pantaleo and Koup, 2004, 
Barouch et al., 2000, Barouch and Letvin, 2000). The high mutation rate and complexity 
of HIV has complicated the development of effective HIV vaccines. 
  
The HIV infects important cells in the human immune system such as CD4 T cells, 
macrophages and dendritic cells. The number of circulating CD4+ cells is greatly reduced 
in HIV-1 infection (Deeks and Walker, 2004, Ho et al., 1995). Thus HIV infected 
individuals will usually present over time with significantly reduced CD4+ T cells in 
their blood (Douek et al., 2003, Douek et al., 2002).  Human immunodeficiency virus 
depletes CD4+ T cells by direct killing of virus infected cells, increasing CD4+ T cell 
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turnover and killing of CD4+ T cells by HIV-1 specific CD8+ T cells (Rowland-Jones et 
al., 1998, Wong et al., 2010, Yang et al., 1997a). Low CD4+ T cells in the blood results 
in the loss of cell-mediated immunity and the body becomes susceptible to opportunistic 
infections (Douek et al., 2003). The drastic loss of CD4+ T cells in the blood eventually 
results in acquired immunodeficiency syndrome (AIDS). This syndrome is characterized 
by an impaired immune system, leading to opportunistic infection such as tuberculosis 
(TB), pneumonia and others (Deeks and Walker, 2004). 
 
HIV infection can be divided into four stages; incubation stage, acute stage, chronic stage 
and full blown AIDS which leads to death. During the incubation stage, the virus infects 
the immune system cells (macrophages, dendritic cells and CD4+ T cells); this stage is 
usually asymptomatic (Kahn and Walker, 1998, Mehandru et al., 2004). The incubation 
period, also known as window period lasts for 2 to 3 weeks, and during this period HIV 
antibodies are beginning to be produced (Deeks and Walker, 2007).  At this stage HIV 
tests will not detect the HIV antibody unless sensitive techniques are used (Feinberg and 
McLean, 1997, Piatak et al., 1993).   The second stage of acute infection is characterized 
by high viral loads and low CD4+ T cell counts in the blood (Pantaleo, 1997, Deeks and 
Walker, 2004). In the acute stage, there is an activation of CD8+ T cells which kill the 
infected cells, resulting in antibody production(Appay et al., 2008a). CD8+ T cells are 
thought to be important in controlling viremia in the acute stage as the CD4+ T cells 
rebound (Pantaleo, 1997). This stage lasts for  approximately 28 days, and includes 
clinical symptoms such as lymphadenopathy, fever, pharyngitis (sore throat), rash, 
myalgia (muscle pain), malaise and mouth sores (Kahn and Walker, 1998).  The third 
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stage is chronic stage or latency, characterized by few or no symptoms and can last for 
two weeks to twenty years or more.  During this stage, HIV is active in the lymphoid 
organs and in the body organs that are rich in CD4+ T cells (Siliciano et al., 2003). Large 
amounts of the virus become trapped in the follicular dendritic cell networks (Siliciano et 
al., 2003, Burton, 2002). The final stage of HIV infection is AIDS and this is usually 
accompanied by symptomatic opportunistic infections (TB, pneumonia, etc). In this 
stage, the CD4+ T cells decline rapidly and fall below 200 cells per µl, and this stage is 




1.2. HIV TRANSMISSION AND PREVENTION 
 
Human immunodeficiency virus is transmitted through infected blood, body fluids such 
as semen, vaginal fluids and breast milk (Ammaranond et al., 2003, Smith et al., 2004). 
There are four main routes of HIV infection: unsafe sex, contaminated needles, breast 
milk and mother to child transmission (Coovadia and Coutsoudis, 2007). However, the 
most common route of HIV transmission is through unsafe sex.  The HIV infected sexual 
secretions of one partner come into contact with the genital, oral or mucous membranes 
of the uninfected partner (Smith et al., 2004). In Southern Africa most transmission 
occurs between heterosexual partners whereas in Western countries homosexual 
transmission is thought to be more common (Boily et al., 2009). Sexual transmission of 
HIV can be prevented by correct and consistent use of latex condoms. It was first 
reported in 1999 that in sub-Saharan Africa  male circumcision may reduce the risk of 
HIV infection (Weiss et al., 2000). Subsequently, randomized clinical trial studies 
conducted in South Africa, Kenya and Uganda showed that men circumcised in sterile 
conditions and given counseling had reduction of HIV transmission for heterosexual sex 
by 60%, 53% and 51% respectively (Bailey et al., 2007, Siegfried et al., 2005). 
 
HIV can also be transmitted through mother-to-child transmission and by multiple 
infection or super infection (Coovadia, 2004, Smith et al., 2004). HIV positive pregnant 
women may  transmit the virus to the child during pregnancy (in utero), during child birth 
(intrapartum) or via breastfeeding (Coovadia, 2004). However, the provision of 
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antiretroviral therapy given during pregnancy reduces the rate of mother-to-child 
transmission to 1%. Initial studies showed that avoidance of breastfeeding after giving 
birth may reduce the transmission of the virus to the child (De Cock et al., 2000). In 
contrast, recent studies report that mothers who are taking antiretroviral drugs may safely 
exclusively breastfeed their children for up to twelve months (Coovadia and Bland, 2007, 
Thior et al., 2006, Smith et al., 2004). Prior to these findings (WHO) developed a policy 
to state that women on ARV may exclusively breastfeed the child for 12 months, 
believing this will reduce mother-to-child transmission (Coovadia et al., 2007).  
 
 
1.3. STRUCTURE OF HIV AND LIFE CYCLE 
 
HIV has a spherical structure with a diameter of 120 nm, approximately 60 times smaller 
than a red blood cell (Chan and Kim, 1998, Freed, 1998). HIV has two copies of positive 
single stranded RNA that codes for nine genes. The single stranded RNA (ribonucleic 
acid) is located inside the nucleocapsid protein, p7 (Mannioui et al., 2005, Freed, 1998). 
Also contained within p7 are the enzymes required for the development of the virion.  
These are reverse transcriptase, protease, ribonuclease and integrase (Freed, 1998). The 
matrix protein also known as p17 is the product of HIV gag gene.  It assists in anchoring 
the gp41/gp120 spike(Chan and Kim, 1998). The envelope protein (Env) is situated on 
the surface of the virus, consisting of three molecules called glycoproteins (gp41, gp120 
and gp160) which assist the virus in anchoring on the cell membrane (Chan and Kim, 
1998, Chan et al., 1997) (Fig. 1). The glycoprotein of the envelope proteins helps the 
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virus to attach and fuse with the host cells and initiate replication (Chan et al., 1997, 
Kuiken et al., 2008). They also promote the fusion of infected cells with neighbouring 
uninfected cells forming synctia (Chan and Kim, 1998). The envelope glycoproteins are 







Figure 1. Structure of Human Immunodeficiency virus.Showing the location of different proteins (Gag, 
Env glycoprotein and the pol-encoded enzymes IN, RT and PR (Freed, 1998). 
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The HIV genome consists of nine genes which encode 19 proteins. These genes are gag, 
pol, env, tat, rev, nef, vif, vpr and vpu (Subbramanian and Cohen, 1994, Cullen, 1992).     
The regulatory proteins of HIV are Tat and Rev.  Nef, Vif and Vpr are accessory proteins 
that confer the ability on HIV to infect cells and to produce new viral copies thereby 
causing disease (Ranki et al., 1994, van Baalen et al., 1997, Hunt, 2010, Miller and 
Sarver, 1997, Trono, 1995). Tat (trans-activator of transcription) consists of 86 to 101 
amino acids depending on the virus subtype (Kuiken et al., 2008, Allen and Altfeld, 
2003). Tat accelerates the production of more HIV virions. HIV strains that do not have 
Tat protein in their genome fail to replicate. Tat induces chromatin remodeling and 
recruits elongation-competent transcriptional complexes on the viral LTR (Zheng et al., 
2005, Gibbs et al., 1995). Tat inhibits LFA-1 mediated Ca2+ influx through the binding of 
L-type Ca2+ channel and impairs NK cell cytotoxicity (Majumder et al., 2009).  Rev, 
another regulatory protein, consists of 116 amino acids including nuclear localization 
sequence (NLS) and nuclear export sequence (NES)(Zheng et al., 2005). The Rev protein 
regulates the expression of HIV proteins by controlling the export rate of mRNAs 
(Cullen, 1998). Rev proteins are involved in shuttling RNA from the nucleus and the 
cytoplasm by binding to RRE RNA (Pond et al., 2009, Pollard and Malim, 1998) while 
the Vif protein counteracts the functions of APOBEC3G (a cell protein which deaminates 
DNA: RNA hybrids and/or interferes with Pol proteins (Zheng et al., 2005, Gandhi et al., 
2008). 
 
Negative factor (Nef) is an accessory protein which is synthesized early in the HIV life 
cycle and is important in disease progression (Lichterfeld et al., 2004b, Collins et al., 
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1998, Page et al., 1997) . The Nef (negative factor) protein manipulates the host’s cellular 
machinery and thus allows infection, survival or replication of the pathogen (Stumptner-
Cuvelette et al., 2001, Page et al., 1997). Nef protein also promotes the survival of 
infected cell by down modulation the expression of Major Histocompability complex –I 
(MHC-1) and CD4 T cells. Nef protein assists the virus to maintain its viral loads and to 
overcome host immune defense resulting in AIDS progression (Sinclair et al., 1997). In 
addition, HIV-1 Nef downregulates CD4+ T cell and MHC proteins which help the virus 
to evade host immune responses (Stumptner-Cuvelette et al., 2001, Cohen et al., 1999, 
Adnan et al., 2006). Gag is one of the most important genes found in all retroviruses and 
is required for assembly of viral proteins (Freed, 1998). It consists of 1,500 nucleotides 
and encodes four separate proteins which are the building blocks for the viral core. HIV-1 
Gag protein has diverse functions in the life cycle of the virus, including viral assembly. 
The Gag protein consists of a subunit called p24, which is a component of the virus that 
is relatively highly conserved. Immune responses against p24 may give strong protection 
since the virus can only avoid these responses at significant fitness cost (Goepfert et al., 
2008, Goulder and Watkins, 2008). Gag and Pol (Polymerase) are next to each other in 
the HIV genome. The pol gene, which is translated as a combined gag-pol reading frame 
encodes for reverse transcriptase and integrase (Freed, 1998). 
 
The viral protein R (Vpr) consists of 96 amino acids and is found in HIV-1, HIV-2 and 
SIV (Le Rouzic and Benichou, 2005). The role of the Vpr protein in AIDS pathogenesis 
is to import viral DNA into the nucleus as a component of pre-integration complex and it 
also plays a role in cell-cycle progression, regulating apoptosis and transactivation of the 
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HIV-LTR as well as host cell genes (Gibbs et al., 1995, Altfeld et al., 2001a, Trono, 
1995, Vodicka et al., 1998). Vpr dysregulates immune system functions by disarming 
both adaptive and innate immune system and also mediates dysregulation of signal 
transduction (Majumder et al., 2009, Le Rouzic and Benichou, 2005, Goh et al., 1998). 
Vpr is normally found in the sera and the cerebrospinal fluid of AIDS patients indicating 
that it may exert biological functions in varied manners. In addition, previous studies 
conducted in monkeys indicate that vpr deletion in SIV results in low viral loads and 
rarely do infected monkeys progress to AIDS (Hadian et al., 2009, Gibbs et al., 1995). 
These results suggest a major role of the vpr gene in disease progression in HIV infection 
(Altfeld et al., 2001a, Emerman and Malim, 1998). Viral protein U (Vpu) is an accessory 
protein with 81 amino acids in size and its promotes the release of new virus particles 
from the infected cells, downmodulation of CD4+ T cells in the endoplasmic reticulum 
and it is also involved in envelope maturation (Pollard and Malim, 1998, Le Rouzic and 
Benichou, 2005, Kuiken et al., 2008, Neil et al., 2008). 
 
1.4. HIV LIFE CYCLE 
 
The HIV life cycle begins when the envelop glycoprotein gp120 binds the CD4 T cell 
receptor and subsequently interacts with other coreceptors such CCR5 (chemokine 
receptor 5) and CXCR4 (C-X-C chemokine receptor type 4) (Freed, 1998, Chan and Kim, 
1998). Transmembrane gp41 induces the membrane fusion reaction that occurs between 
the lipid bilayer of the virion and the host cell plasma membrane. This process leads to 
the release of the viral core into the host cell cytoplasm (Chan and Kim, 1998, Wyatt and 
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Sodroski, 1998). The virus uncoats inside the cell cytoplasm.  During this process the 
capsid (CA) is lost, while the matrix (MA), nucleocapsid and other polymerase encoded 
enzymes (integrase and reverse transcriptase) are retained (Zheng et al., 2005, Chan et al., 
1997, Freed, 1998) (Fig. 2). During the uncoating process, reverse transcription takes 
place, whereby viral RNA reverse transcription to double strand DNA is largely 
completed. Mutations often take place during the  reverse transcription process and these 
may lead to drug resistance and allow the virus to evade the immune system (Freed, 
1998). A high-molecular weight complex is then formed and is referred to as the pre-
integration complex.  It is then transported into the nucleus across the nuclear membrane. 
Inside the nucleus, the viral DNA is integrated into the host DNA; this is catalyzed by 
integrase (Zheng et al., 2005) (Fig. 2). The provirus or integrated DNA will then serve as 
templates for mRNA synthesis (Zheng et al., 2005). 
 
The integrated DNA provirus is transcribed into mRNA and then spliced into small 
pieces. The mRNA is transported into the cytoplasm and envelope glycoproteins are 
synthesized in the endoplasmic reticulum (Chan et al., 1997). They are transported to the 
plasma membrane through the secretory pathway. Gag and Gag-pol polyprotein 
precursors are transported by an unknown mechanism into the plasma membrane (Freed, 
1998).  After transportation into the plasma membrane, Gag precursor recruits two copies 
of ssRNA which interact with the Gag-pol precursors. They are then assembled into 
structures which are visible by electron microscopy (EM) structures leading to the 
formation of buds. After budding, viral particles cleave the Gag and Gag-pol region 
polyprotein precursor into mature proteins (Freed, 1998) (Fig. 2). Structural proteins Gag 
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and Env are produced from the full length mRNA. The final stage of the viral cycle is the 
assembly of new HIV-1 virions which begins at the plasma membrane (Freed, 1998). 
These pieces are transported into the cytoplasm where they are translated into regulatory 
proteins (Tat) and (Rev) (Pollard and Malim, 1998, Pond et al., 2009). The mature virus 




































Figure 2.  The HIV replication cycle. 
HIV infects the CD4 T cells using gp120 of the envelope, HIV RNA is then released inside the host cells. 
HIV RNA is reverse transcribed into DNA which is then integrated into the host’s DNA. Viral DNA is then 
transcribed into viral RNA followed by protein translation inside the cytoplasm and new virus is released 




1.4. IMMUNE RESPONSE TO VIRAL INFECTION 
 
The immune system is the protective mechanism for the body against any foreign 
particles that enters into the body. It consists of the innate (non-specific) and adaptive 
(specific) immune system. The adaptive immune system comprises of B lymphocytes and 
T lymphocytes. B lymphocytes mature into memory B cells which then become plasma 
cells that produce antibodies, also known as immunoglobulins.  T lymphocytes consist of 
CD4 T cells (helper cells) and CD8 T cells (killer cells). Cytotoxic T cells mature into 
memory T cells which express perforins that lyse the target APC. They also produce 
cytokines and chemokines which kill virus infected cells (Hickling, 1998). 
 
 The innate immune system includes the skin, mucosa, complement system, natural killer 
cells and intrinsic immunity. NK cells are important for tumor surveillance and they can 
secrete several cytokines (IFN-γ, IL-1, TNF-α). NK cells secreting IFN-γ can influence 
the immune system by promoting differentiation of type 1 T cell and of type 2 cells.  
Natural killer cells are thought to be the most important component of innate immunity, 
which is also thought to play a crucial role in control of HIV (Martin et al., 2002). Host 
genetic studies indicate that individuals who co-express KIR3DS1 (a regulatory receptor 
on the surface of NK cells) and HLA-Bw4-081 (HLA-alleles that presumably binds to 
KIR3DS1 and activates NK cells are associated with low viral loads and slow disease 
progression (Martin et al., 2002). It was then reported that HIV controllers are enriched 
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with certain NK cells receptors which suggests that NK cells play a role in disease 
outcomes (Vieillard et al., 2010). 
 
T lymphocytes are very important in the immune system, especially CD8 T cells because 
they kill the viral infected cells using  either cytotoxic or non-cytotoxic pathway (Borrow 
et al., 1994). CD8 T cells recognize antigens that are presented by MHC-I molecules 
while CD4 T cells recognize antigen presented on MHC- II molecules (Hickling, 1998). 
CD8 T cells are responsible for destroying viral infected cells. The major 
histocompability complex (MHC) is divided into two classes, MHC class I and II. Class I 
molecules are found in all nucleated cells, except red blood cells whereas class II 
molecules are found on antigen presenting cells (APC), including dendritic cells, 
macrophages and B cells (Simpson, 1988, Groothuis et al., 2005). Studies indicate that 
MHC genes are involved in controlling both humoral and cell-mediated immune 
responses (Groothuis et al., 2005).  
 
Major Histocompability Complex-I (MHC-I) molecules are glycoproteins with two non-
covalently associated polypeptide chains known as the light chain and heavy chain (Kosc 
et al., 1998, Simpson, 1988).  The light chain is commonly known as β2 microglobulin 
and the heavy chain is known as α chain. The two α chains (α1 and α2) fold up to form a 
peptide binding groove, however MHC-I may bind peptides 8-10 amino acids long while 
MHC-II binds longer peptides (Kosc et al., 1998, Simpson, 1988, Groothuis et al., 2005). 
Human beings may have a maximum of six different MHC-I products and slightly more 
for MHC-II. A MHC molecule has one binding site and can only bind one peptide at a 
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time (Groothuis et al., 2005). A peptide must be associated with a given MHC of the 
individual or else an immune response is not initiated.  
 
MHC molecules are encoded for by several genes in humans known as human leucocyte 
antigens (HLA gene) and the most well researched of these are HLA-A, B, C, DPAI, 
DPBI, DQAI, DQBI, DRA, DRBI (Groothuis et al., 2005, Mallal et al., 1990). They are 
divided according to the MHC classes; HLA-A, B, C belong to class I and D belongs to 
class II. The HLA molecules are located on the surface of antigen presenting cells (APC). 
HLA-A and HLA-B restricted epitopes play a significant role in controlling HIV 
replication (Goulder and Watkins, 2008, Kiepiela et al., 2007). However, the role of 
HLA-C restricted CD8+ T cell is not well studied and is possibly underestimated in HIV 
control. This may be due to less expression of HLA-C alleles on the cell surface 
compared to HLA-A and HLA-B (Goulder et al., 1997a). Studies have suggested that low 
surface expression of HLA-C alleles may result from weak binding of β2 microglubulin 
(β2m) (Zemmour et al., 1992). Linkage disequilibrium of HLA-C with other HLAs may 
also result in underestimating its role in the control of HIV (Goulder et al., 1997a, 













1.5. ROLE OF CYTOTOXIC T CELLS RESPONSES IN HIV PATHOGENESIS. 
 
HIV-1 specific CD8+ T cells play a vital role in the control of HIV replication and this 
has been proven by the decline in HIV/SIV viral loads after HIV acute infection, 
coinciding with an increase in HIV specific CD8+ T cells (Hess et al., 2004, Evans et al., 
1999, Borrow et al., 1994, Klatt et al., 2010).  However, differences exist in their antiviral 
effectiveness based on their HLA restriction, epitope specificity, functional epitope 
avidity, targeted viral protein (Kiepiela et al., 2007, Altfeld et al., 2006). CD8+ T cell 
depletion performed in animal models indicates that absence of CD8+ T cell is associated 
with high viral load (Schmitz et al., 1999, Fauce et al., 2007). Most recent studies have 
demonstrated that CD8 T cell depletion results in the rise in viral loads to its acute 
infection peak (Wong et al., 2010, Klatt et al., 2010).  
 
In addition, there is also consistent association between certain HLA-class 1 molecules 
and the control of viral replication (Migueles et al., 2003, Kiepiela et al., 2004, Altfeld et 
al., 2006).  These findings have supported the view that effective HIV-1 specific CD8+ T 
cell immunity controls viral replication. There are many studies that have shown 
significant evidence that CD8+ T cells play a crucial role in both HIV and SIV 
replication (Yang et al., 1997a, Walker and Burton, 2008, Koup et al., 1994). However, 
there was no significant association between the number of HIV-1 specific CD8+ T cells 
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and virological control when responses are measured by ELISPOT or intracellular 
cytokine staining (ICS) assay (Addo et al., 2003, Altfeld et al., 2001b).  
 
The mechanism of how CD8+ T cells inhibit viral replication is still under investigation. 
In addition, HIV infection leads to the decline of CD4+ T cell and the virus infects and is 
associated with disease progression (Vasan et al., 2007, Appay et al., 2008b). Previous 
studies reported that CD8+ T cells kill viral infected cells either via cytolytic or non-
cytolytic pathways (Yang et al., 1997b, Rowland-Jones et al., 1998). The protective role 
of HLA-B*27 and HLA-B*57 alleles in human as well as Mamu-B*17 and Mamu-A*01 
in macaques is well established and the epitopes restricted by these alleles are well 
defined (Migueles et al., 2003, Mothe et al., 2003, Maness et al., 2008). HLA-B*57 
alleles in HIV controllers have an ability to  present a broad number of HIV peptides for 
T cell recognition and also generate high magnitude of CD8+ T cell responses (Altfeld et 
al., 2003a, Migueles et al., 2003).  
 
Many HIV positive individuals can control viremia for a long time without progressing to 
AIDS while others progress faster to disease or others maintain undetectable viral loads 
for long time, these individuals may provide important information in vaccine design 
strategy (Migueles and Connors, 2001, Deeks and Walker, 2007, Friedrich et al., 2004). 
There is a group of individuals who are known as elite HIV controllers, this group 
presents with viral load <50 copies/ml and high CD4 T count after long time of HIV 
infection. Some elite HIV controllers may be infected with replicative-incompetent virus 
(Blankson et al., 2007, Bailey et al., 2009, Lassen et al., 2009). Blankson et al (2007) 
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used a highly sensitive co-culture assay to isolate the virus successfully from elite 
controllers. Studies performed by Blankson et al where two viruses were isolated and 
sequenced; one virus from the plasma and the other one from the resting CD4+ T cells 
(archived virus) revealed that the plasma virus contained mutations in HLA-B*57 
restricted epitopes and very rarely on archived virus (Bailey et al., 2006b, Blankson et al., 
2007). In addition, the same group of researchers showed that CD8+ T cells mediated 
selective pressure on plasma virus in elite controllers and suggested that there must be 
ongoing HIV-1 replication in spite of very low viral loads (Bailey et al., 2009). 
 
HIV controllers have more functional CD8+ T cells compared to non-controllers and they 
are also likely to target the conserved proteins of HIV (Altfeld et al., 2003b, Addo et al., 
2007). HLA-B*27 and HLA-B57 alleles are overrepresented in the HIV controllers or 
long-term nonprogressors indicating a major role for MHC-I molecules in controlling 
HIV replication. The multiepitopic and de novo CD8+ T cells response of HIV 
controllers have an ability to suppress viral replication despite escape mutations (Bailey 
et al., 2006a). Likewise, in a cohort of 578 chronic HIV infected subjects, it was 
demonstrated that only Gag-specific CD8+ T cell responses were associated with lower 
HIV viremia, including those who have HLA-B*57 (Kiepiela et al., 2004, Sacha et al., 
2007). Even in the acute phase of infection HLA-B*57 allele was associated with viral 
control (Migueles et al., 2003). This demonstrates that host genetic factors may influence 
HIV pathogenesis and may provide a functional link between HLA-B*57 and viral 




Previous studies reported that mutations within Gag may induce a viral fitness defect 
while mutations within highly variable region like envelope (Env) may impact less on 
viral growth kinetics (Leslie et al., 2005, Goulder et al., 2001c, Crawford et al., 2009). 
Changes in epitope sequences may affect the recognition and also interfere with the 
peptide processing and affect their presentation on the cell surface of SIV or HIV infected 
cells (Koup et al., 1994, Leslie et al., 2004). Studies have reported that changes in epitope 
amino acid sequences especially in immunodominant Gag-restricted epitopes may result 
in the loss of recognition of the virus by cytotoxic T cell responses (Barouch and Letvin, 
2002, Gao et al., 1999). Moreover, escape mutations may decrease the fitness of the virus 
which may facilitate disease progression. However, other studies show that there is 
significant correlation between the number of Gag escape mutations targeted by specific 
HLA-B-restricted allele and reduced viral loads, therefore transmission of HIV-1 Gag but 
not Nef immune escape mutations is associated with reduced viral loads (Goepfert et al., 
2008).  
 
However, cohorts of HLA-B5701+ patients show that mutations within the p24 Gag 
peptide presented by the HLA-B5701 allele reduce the replicative capacity, but these do 
not lead to virologic rebound (Migueles et al., 2003). When a HLA-B*5701 positive 
individual transmits the virus to a non-B*5701 individual mutations may revert and the 
gag mutations may increase the viral fitness (Leslie et al., 2006).  Additionally, Gag 
restricted epitopes are recognized by CD8+ T cells after 2 hours post infection, before 
integration and protein synthesis, while Env-derived epitopes were recognized after 18 




Genomic studies have reported the association of HLA-C locus and other genetic variants 
with an ability to control HIV (Fellay et al., 2007). Recent genome wide studies 
conducted in HIV infected individuals from nine cohorts identified allelic polymorphisms 
associated with viral set point (HCP-5 and 5’ HLA-C) or disease progression (RNF-39 
and ZNR1) (Fellay et al., 2007, Thomas et al., 2009, Han et al., 2008). In addition, a 
population-based association study revealed complete linkage disequilibrium between 
HCP5 and HLA-B*5701/Cw*06 (Thomas et al., 2009, Han et al., 2008).  However, other 
studies reported a crucial contribution of sub-dominant HLA-C restricted CTL responses 
to HIV replication when the linkage disequilibrium with other HLAs has been corrected.  
 
Additionally, surface expression increased and HIV/AIDS control is associated with a 
variant upstream of HLA-C alleles (Han et al., 2008, Thomas et al., 2009). These studies 
concluded that the -35C allele is a proxy for high HLA-C cell surface expression 
(Thomas et al., 2009). Though HLA-C alleles are not downregulated by HIV-1 Nef 
protein, the HLA-C expression pattern may have a significant role in HIV pathogenesis 
(Adnan et al., 2006, Makadzange et al., 2010). Individuals with high surface expression 
of HLA-C are associated with slow disease progression. HLA-B*27 and B*57 alleles are 
also known to be associated with the control of HIV replication especially when 
presenting immunodominant Gag epitopes (Streeck et al., 2007, Altfeld et al., 2006).  
In acute HIV infection, there is a rapid and extensive destruction of CD4+ T cells 
populations that reside in the gut-associated lymphoid tissues (Mehandru et al., 2004). 
Other studies show that gut CD8+ T cells are more polyfunctional compared to peripheral 
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CD8+ cells and upon initiation of ART the rectal polyfunctional HIV Gag-specific CD8+ 
T cells were reduced (Critchfield et al., 2008, Brenchley and Douek, 2008). Evidence 
from animal models showed that SIV infection causes half or more of the gut CD4+ T 
cells depletion during primary infection. The CD4+ T cells loss results in the loss of 
mucosal integrity leading to malfunctioning of the gut (Li et al., 2005). All these events 
happen before adaptive immunity takes over, therefore early host immune responses are 




1.5. POLYFUNCTIONAL CD8+ T CELL RESPONSES IN HIV 
 
CD8+ T cells kill viral infected cells by secreting cytokines (IFN-γ, TNF-α, IL-2), 
chemokines (MIP-1β), and expression of the degranulation marker (CD107a). CD8+ T 
cells that display all these functions are referred as to “polyfunctional” (Pantaleo and 
Koup, 2004, Betts et al., 2006, Harari et al., 2007). Previous studies indicated that in 
primary infection CD8+ T cells are polyfunctional but as the disease progresses their 
functions deteriorate resulting in high viral loads (Rehr et al., 2008, Streeck et al., 2008, 
Daucher et al., 2008). These studies reported that the loss of polyfunctional CD8+ T cells 
in chronic HIV infection is a consequence of the antigen load and antigen persistence and 
this may mean that viral burden impacts the natural functions of CD8+ T cells (Streeck et 
al., 2008).  Likewise,  in chronic HIV infection, HIV specific CD8+ T cells become  
monofunctional, frequently producing only IFN-γ or MIP-1β or CD107a (Betts et al., 
2006, Zimmerli et al., 2005, Harari et al., 2007). HIV-1 specific   CD8+ T cells 
progressively lose their functions during chronic infection and this is characterized by 
inability to produce particular cytokines such as IL-2 (Lichterfeld et al., 2004a). In most 
immunological studies, IFN-γ-production by CD8+ T cells was used to determine the 
magnitude of immune responses against the virus (Kiepiela et al., 2004). 
 
The effectiveness of HIV-specific immune responses does not rely on the quantity of 
responses, but on the quality of CD8+ T cells (Daucher et al., 2008). HIV-specific CD8+ 
T cells play a vital role in the control of HIV replication and disease progression (Borrow 
et al., 1994, Koup, 1994, Schmitz et al., 1999, Altfeld and Allen, 2006). However, 
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differences exist in their antiviral effectiveness based on their HLA restriction, epitope 
specificity, functional epitope avidity and targeted viral protein (Kiepiela et al., 2007, 
Bihl et al., 2006, Yang et al., 2003). In particular, major histocompatibility complex 
(MHC) class I molecules have been shown to differ in their ability to mediate the control 
of HIV and SIV replication in humans and non-human primates respectively (Rolland et 
al., 2008, Kiepiela et al., 2004). For example, virus-specific Gag CD8+ T cell responses 
restricted by HLA-B*57, HLA-B*5801 and HLA-B*27 are associated with low viral 
loads or slow disease progression in HIV infection while Mamu-A*01 and Mamu-B*17 
restricted responses are associated with control in SIV infection of rhesus macaques 
(Chung et al., 2007, Migueles et al., 2003, Loffredo et al., 2008, Maness et al., 2008).  
 
In contrast to the beneficial outcomes associated with the protective MHC allele-
restricted Gag CD8+ T-cell responses, Gag HLA-Cw*-restricted CD8+ T-cell responses 
were found to be associated with high viral loads (Kiepiela et al., 2007).  Paradoxically, 
although HLA-Cw*-restricted CD8+ T lymphocytes appear to contribute little or even 
negatively to viral control in vivo, HLA-C is not down-regulated by HIV-1 Nef from the 
surface of infected cells to the same extent that HLA-A and HLA-B molecules (Cohen et 
al., 1999, Collins et al., 1998).  Overall, the mechanisms underlying control of HIV by 
protective alleles such as HLA-B*57/5801, or the lack of control by HLA-Cw alleles 




HIV-specific CD8+ T cells may also display different differentiation status and activation 
profiles (Appay and Sauce, 2008b, Papagno et al., 2004). It has been suggested that these 
phenotypic differences are associated with divergent functional antiviral capacities of 
virus-specific T-cells (Almeida et al., 2009). Some studies have suggested that 
polyfunctional CD8+ T cells, able to secrete up to five different effector functions (IFN-
γ, IL-2, TNF-α, MIP-1β and CD107a), have better antiviral activity (Betts et al., 2006, 
Precopio et al., 2007, Daucher et al., 2008). CD8+ T cell responses restricted by HLA-
B*27 and HLA-B*57 alleles were reported to be polyfunctional when compared to CD8+ 
T cell responses restricted by HLA-A alleles within the same patients (Harari et al., 
2007).  However, recent data have suggested that the functional profile of CD8+ T cells 
is largely a consequence of the duration and level of antigen load, with prolonged 
continuous exposure to high levels of antigen resulting in exhausted CD8+ T cells 
characterized by a monofunctional effector profiles (Streeck et al., 2008, Rehr et al., 
2008). 
The aim of this study was to optimally define HLA-Cw* restricted CD8+ T cell 
responses in the Sinikithemba cohort in the Durban. The second aim was to investigate 
the polyfunctionality profiles of immunodominant HLA-B and HLA-Cw*-restricted 
CD8+ T cells in a cohort of HIV-1 clade C chronically infected individuals displaying 
both responses. This provided the unique opportunity to examine HLA-B and Cw* 
restricted responses in the context of matched viral loads and CD4 cell counts.  The main 
focus was on the immunodominant HLA-B*57/5801 epitopes in Gag p24 and the 
immunodominant HLA-Cw*07 restricted epitope KY11 in Nef, in persons possessing 
both responses. We hypothesized that HLA-B CD8+ T cells will display a more 
30 
 
polyfunctional phenotype compared to HLA-Cw*-restricted CD8+ T cells. We also 
aimed to determine whether sequence variation within epitopes presented by these two 
alleles has a bearing on the magnitude and polyfunctionality of epitope-specific CD8+ T 
cell responses. The relationship between the frequency of polyfunctional HIV-1-specific 
CD8+ T cells and CD4+ T cell counts and viral loads was also investigated. 
 
1.6. MAIN OBJECTIVES 
 
1. To optimally define novel HLA-Cw* restricted HIV-1 specific CD8+ T cell epitopes in 
a cohort of individuals with chronic untreated HIV-1 clade C infection in Durban. 
2. To assess the polyfunctionality of immunodominant HLA-Cw* and HLA-B*57/5801 
restricted CD8+ T cells within the same study subjects and to investigate  the  impact 
sequence variation on T cell polyfunctionality in the same individuals. 
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Chapter 2.  Material and Methods 
2.1 BACKGROUND AND PRINCIPLES OF 
IMMUNOLOGICAL ASSAYS 
2.1.1 ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS ASSAY 
 
Peripheral blood mononuclear cells (PBMC) are blood cells which have round shaped 
nuclei (lymphocytes and monocytes). These cells play an important role in immune 
defence mechanisms against infection. They were separated from the whole blood 
samples using density centrifugation procedures. In the procedure, whole blood is layered 
over histopaque, a separation medium. After centrifugation, three layers are observed 
from top to bottom. The middle layer is the PBMC layer and this is carefully removed 
and washed to remove contaminants. Isolated PBMCs are used for different purposes: to 
assess the level of biological immune function, to quantify specific cell phenotype (T and 
B lymphocytes), and to determine the amount of specific drug within these cells and 
evaluate in vitro, the influence of a test drug on lymphocytes. PBMCs can be frozen 
using 10% DMSO in fetal calf serum and kept in liquid nitrogen for later use. However, 
without an effective and careful isolation, freezing and thawing of cells can detrimentally 









2.1.2 ENZYME-LINKED IMMUNOSPOT ASSAY 
 
Enzyme-linked immunospot assay is adapted from the ELISA assay; it measures the 
concentration of cytokines that are released from CD8+ T cells stimulated with antigen. 
Enzyme-linked immunospot (ELISPOT) assay is widely used to measure the magnitude 
of responses of cytokine-producing cells when stimulated with specific HIV antigen (Fu 
et al., 2007, Maecker et al., 2001, Hickling, 1998). It is an effective assay for quantifying 
host immune responses, but it does not provide information about the quality of the 
immune response (Mwau et al., 2002, Chung et al., 2007). It provides information on the 
quantity of CD8+ T cells producing cytokines upon antigen stimulation (Fu et al., 2007). 
It is a very rapid, sensitive assay and allows multiple screening of multiple CD8+ T cell 
samples on a single day. The ELISPOT assay is widely used in evaluating immune 
responses in vaccine studies (Chung et al., 2007, Mwau et al., 2002); vaccines can elicit 
HIV-1 specific T cell immune  responses which can be detected  using ELISPOT, 
however  some of this responses  lack  functional avidity to recognize HIV-1 infected 
cells (Bennetts et al., 2007, Arrode et al., 2007).  
 
The ELISPOT assay results show the efficiency of a vaccine to induce an immune 
response; however, functional assays for vaccine development are also required 
(Hickling, 1998). The MHC-peptide tetramer staining assay is used to detect T cell 
receptor of a particular specificity irrespective of their functionality (Mwau et al., 2002, 
Goulder et al., 2001a, Hickling, 1998). In both intracellular cytokine staining (ICS) and 
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the ELISPOT assay, the whole protein, viral lysate or specific peptide may be used as 
antigen. In principle, the host antigen presenting cells (APC) process the antigen through 
the exogenous pathway of antigen presentation. Thereafter the peptide is presented on 
MHC- class II molecules and recognized by CD4+ T cells which proliferate and produce 
cytokines, similarly CD8+ T cell responses require antigen to be processed via the 
endogenous pathway of antigen presentation resulting in peptide presentation on MHC-
class I molecules (Maecker et al., 2001).   
In this assay, the 96-well plate is covered with PVDF membrane, and  the bottom of each 
well is coated with primary antibodies that are specific to the protein of interest, for 
example cytokines, antibodies, surface marker, receptor. Peripheral blood mononuclear 
cells (PBMC) are cultured in an ELISPOT plate (Fig.3). Antigen or peptides are added 
into each well to stimulate the secretion of IFN-γ, which binds to the well bottom by 
forming a complex with antibodies (Mwau et al., 2002). The binding of antigen is very 
specific and therefore only molecules of interest stick to the bottom membrane. After 
incubating the cells and antigen overnight, the content of the well is discarded and the 
plate is washed with PBS thoroughly. Proteins remain bound at the bottom of the well. 
Biotinylated secondary antibody is added which binds to another epitope of the primary 
antibody protein and this is incubated for 90 minutes at most. The next step is to add 
enzyme that is coupled with streptavidin, which binds covalently with biotin, the marker 
of the secondary (detection) antibodies (Fig. 3). Multiple washing of the plate removes 
the excess of enzyme that remains unbound. The substrate is then added, which in the 
presence of enzyme changes into dye, BCIP/NBT is added (5-brom0-4-chloro-3-indolyl 
phosphate and nitroblue tetrezolium). The dye coated under catalytic influence of the 
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enzyme, sediments on the well bottom. After visible spots develop colour reaction can be 
stopped through washing and drying the plate. In the ELISPOT assay, it is assumed that 
one spot denotes one cell producing cytokine or protein of interest. The spots are counted 
using a specialized ELISPOT plate reader (Hickling, 1998). The number of spots 
produced by cells is expressed as spot forming units (SFU). 
 
2.1.3. INTRACELLULAR CYTOKINE STAINING ASSAY 
 
Intracellular cytokine staining (ICS) is a widely used technique in flow cytometry which 
measures the cytokine production upon antigen stimulation (Waldrop et al., 1997, 
Hickling, 1998).  In this assay, T cells are stimulated with specific peptide in vitro for 
about one and half hour. Brefeldin A or monensin is added to the tube in order to block 
the transport of cytokine through the Golgi apparatus, which will prevent the secretion of 
protein products such as cytokines. Fixation and permeabilization of T cells is crucial 
because it allows cytokine specific antibodies to enter the cells. After fixation and 
permebialization the cells are stained for the presence of intracellular cytokines using 
directly conjugated anti-cytokine antibodies (Prussin and Metcalfe, 1995, Hickling, 
1998). Intracellular cytokine staining has several advantages on measuring cytokine 
staining. Large number of CD8+ T cells can be analyzed in a very short time and multiple 
cytokines can be measure at the same time (polyfunctionality of CD8+ T cells measuring 
IFN-γ, IL-2, TNF-α, MIP-1β and CD107a). It can also be used to determine the 
phenotype of the cells that are producing cytokines. In addition, ICS has been used 
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successfully to characterize cytokine production by circulating CD4+ T cells in HIV 



















Figure 3. Schematic diagram showing the Enzyme-linked immunospot assay. 
a) PBMCs with antigen in the cell culture, b) ELISPOT plate pre-coated with anti-cytokine antibody c) 
Cells are incubated with antigen on a pre-coated plate, d) Cells with antigens are incubated overnight for 
maximum secretion of cytokine, e) wash off the cells and coat the plates with secondary antibody and 
incubate for 1h 30 min, f) wash off the secondary antibody) add streptavidin and incubate for 45 min at 
room temperature in the dark, h)wash off the plate and add colour reagents to develop the spot NBT/BCIP 




2.1.4 FUNCTIONAL AVIDITY 
 
CD8+ T lymphocytes possess the antibody-like T cell receptor (TCR) which binds 
antigen or foreign molecule, this binding initiates events that lead to the neutralization or 
eradication of foreign molecules (Margulies, 2001). TCR generates a repertoire of 
diversity in the thymus through somatic recombination. However, intrinsic affinity is 
commonly used to refer to the basic thermodynamic parameter, the equilibrium constant 
KD that describes a single equilibrium binding reaction (Margulies, 2001, Bennetts et al., 
2007). Functional avidity implies the ability of a particular T cell population to respond 
to the stimulation provided by tittered MHC-peptide complex (Yang et al., 2003, Bihl et 
al., 2006).  
 
Functional avidity refers to the lowest peptide concentration that elicits half the maximal 
responses when stimulated with specific peptide (Bihl et al., 2006, Honeyborne et al., 
2006). Avidity measurement depends on distal biological readout, and it may only 
indirectly reflect intrinsic affinity of the key components in the proximal events 
(Margulies, 2001). It may result from many interactions and steps, the relationship of 
intrinsic affinity of the particular TCR for its cognate peptide-MHC complex can at best 
be an approximation (Bennett et al, 2007). Immunological techniques have been 
developed to assess peptide functional avidity; these assays assess the secretion of IFN- γ 
when stimulated with the immunodominant peptide (Bihl et al., 2006). Peptide sensitivity 
is an important parameter in determining the efficacy of viral clearance by CD8 T cells. 
CD8 T cells with high responses at low concentration of peptide are termed as high 
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avidity and those that need high concentration are low avidity (Bennetts et al., 2007, Bihl 
et al., 2006). Functional avidity is a measure of the overall strength of the interaction 
between CTL and the target cell. Surface molecules of CTL are capable of contributing to 
the overall functional avidity of the cells. In addition, TCR affinity plays a role in 
determining the sensitivity of a CTL to peptide. 
 
In addition, some studies have associated HLA-B* restricted CD8 T cells epitopes with 
high functional avidity as compared with HLA-A and HLA-C restricted epitopes (Bihl et 
al., 2006). Moreover, HLA-B alleles are associated with effective antiviral immunity 
compared to other HLA-A and C alleles (Kiepiela et al., 2007, Altfeld et al., 2003a). It 
has been reported that HIV-1 specific CD8 T cell in the early infection of HIV display 
high functional avidity compared to HIV-1 chronic infection (Lichterfeld et al., 2007). 
The changes in functional avidities in early and chronic HIV-1 infection was linked to a 
substantial switch in the clonotypic composition of epitope specific CD8 T cell resulting 
from the preferential loss of high avidity CD8 T cell (Lichterfeld et al., 2007). The loss of 
high avidity HIV-1 specific CD8+ T cell in chronic infection is due to the high level of 
viral replication which then impairs the functionality of CD8 T cell (Yang et al., 2003). 
Since HIV-1 specific CD8 T cells have high functional avidity in early infection, this 
might reflect higher overall avidity of the TCR/peptide MHC-1 interaction in early 
infection. This can be measured by using tetramer dissociation assay (Savage et al, 1999). 
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2.1.5 REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT- 
PCR) 
 
Polymerase chain reaction (PCR) is the assay that is used to amplify a single or few 
copies of DNA, in order to make more copies for different purposes. It provides a 
sensitive means of amplifying small quantities of DNA. It is widely used in molecular 
biology, immunology, genetics, diagnostics, clinical and forensic laboratories. In making 
up the PCR products from plasma RNA, SuperScriptTMIII One-step RT-PCR system with 
Platinum® Taq High Fidelity was used. This is designed for sensitive, high-fidelity end-
point detection and RNA analysis by RT-PCR. In this procedure both cDNA synthesis 
and PCR purification can be performed in a single tube using gene-specific primers, 
which can target RNAs and mRNA.  
 
The one-step RT-PCR kits has the mixture of Superscript®III reverse transcriptase and 
PlatinumTM Taq DNA polymerase High Fidelity for enhanced RT-PCR yields and 
fidelity, and it can also detect longer templates. It can detect a range of RNA target from 
as small as 300bp to 10 kb and one can start from 1 pg to 1µg of total RNA. These two 
enzymes are engineered to reduce RNase H activity and provide increase thermal 
stability. The mixture of the two enzymes can synthesize cDNA at a temperature range 
from 45-60oC, increasing specificity and high yields of cDNA and more full length 






Platinum® Taq DNA polymerase high fidelity consists of recombinant Taq DNA 
polymerase, Pyrococcus species GB-D polymerase and Platinum® Taq antibodies. This 
may block the polymerase activity at ambient temperature. The denaturation of the 
antibodies results in polymerase activity restoration, during denaturation step in PCR at 
94oC which brings about a hot start, increasing the sensitivity and specificity and yield 
(Chou et al., 1992, Sharkey et al., 1994). This mixture of enzymes results in a six-fold 
increase in fidelity and allows amplification of simple and complex DNA templates.  The 
2x reaction mix has a propriety buffer system that has been optimized for reverse 







2.2. STUDY PATIENTS 
 
The Sinikithemba cohort has 451 chronic HIV-1 infected individuals whose time of 
infection is unknown. The cohort, established in 2003 at McCord Hospital, Durban, 
South Africa consists of antiretroviral naïve patients (Kiepiela et al., 2007, Kiepiela et al., 
2004). In this cohort, the HLA-C restricted CD8+ T cell responses were quantified using 
ELISPOT and intracellular cytokine staining assay (Fig. 4). 
 In this study population, Cw*0701 is in linkage disequilibrium with B*5801 (p=0.0239) 
and B*5703 (p=0.0097) and B*5702 (p=0.0034) as determined by the HLA linkage 
disequilibrium tool on the Los Alamos HIV database 
(http://www.hiv.lanl.gov/content/immunology/hla/hla_linkage.html).  
In B*5702/5703-positive subjects, 64% co express Cw*07, and in B*5702/5703-positive 
subjects who do not express Cw*0701, 97% co express Cw*1801. In B*5801-positive 
subjects, 65% co express Cw*07 and in 88% of the remainder either Cw*0302 or 
Cw*0602 were co expressed with B*5801.  Furthermore, nine HIV-1 infected patients 
were selected from the 78 patients from Sinikithemba cohort in order to study the CD8+ 
T cell polyfunctionality. The nine subjects studied  for polyfunctionality assay were 
selected based on the possession of concurrent immunodominant HLA-B*57/5801- and 
HLA-Cw*07-restricted CD8+ T cell responses detected by gamma interferon (IFN-γ) 
ELISPOT, defined as a minimum magnitude of 500 spot forming cells per million 









Figure 4. Schematic Diagram showing the selection of the study subjects.  
The Sinikithemba cohort consists of 451 chronic HIV-1 infected individuals. All these patients were 
screened for immune responses using ELISPOT assay. A total of seventy eight patients with HLA-Cw* 
restricted CD8+ T cell responses were further assessed by intracellular cytokine staining. The remaining 
three hundred and seventy three patients were not studied because they did not have positive HLA-Cw* 
restricted responses on the ELISPOT assay.  From the seventy eight patients who were studied, thirty 
seven  possessed both HLA-B*57/5801 and HLA-Cw*7 restricted responses. From these thirty seven  
individuals, nine had immune responses ≥500 SFU/million PBMCs. These nine individuals were used 
for the polyfunctionality studies. 
37 chronic HIV-1 infected patients 
coexpressing HLA-B*57/5801 and HLA-
Cw*restricted responses. 
9 chronic HIV-1 infected patients with both HLA-B57/5801 
and HLA-C restricted responses of more than 500 
SFU/million from ELISPOT assay. 
Functional avidity from dominant HLA-C 
restricted epitopes; optimal definition of 
new peptide (Finemapping). 
Polyfunctionality of dominant HLA-B*57/5801 and 
HLA-Cw7-KY11 within each patient. Sequencing of Gag 
and Nef genes. 
78 chronic HIV-1 infected patients 
were characterised by IFN-γ ELISPOT 
assay and quantify by ICS. 
373 chronic HIV-1 infected patients 
without HLA-Cw* restricted CD8+T 
cell responses in IFN-γ ELISPOT 
assay. 
Four hundred and fifty one chronic 
HIV-1 infected patients from 




2.2.1 PROTOCOL OF PBMC SEPARATION 
 
In lymphocytes separation, reagents must be sterile and kept inside the Class II Biological 
Safety Cabinet (BSC). Before placing objects in the Class II BSC, they were wiped down 
with 70% ethanol; 50 ml conical tubes were used in lymphocytes separation. The blood, 
PBS with antibiotics and histopaque were added in 1:1:1 ratio. The maximum amount of 
the blood that was separated in 50 ml conical was 45 ml. The tubes were labeled with the 
patient’s ID and the date of sample collection. The histopaque media was added to the 
bottom of 50ml conical flask. The blood was pooled from Lithium heparin tubes (green 
top) or from EDTA tubes (purple top) to the 50 ml conical flask using 10 ml pipette with 
pipette aid. The blood was diluted with PBS supplemented with antibiotic (pen/strep). 
The amount of PBS used was equal to the amount of blood. The blood and PBS with 
antibiotics were mixed up with pipette aid using a 10 ml pipette. The empty blood tubes 
were discarded into the 20% Virkon or any other appropriate disinfectant. The blood and 
PBS were mixed, and then slowly layered on top of the histopaque in the labeled conical 
tubes taking care not to mix with histopaque. The layered blood was then centrifuged at 
room temperature for 30 minutes at 1,500 rpm with a slow start and no brakes. During 
spinning the empty 50 ml conical tubes were labeled with patient details. After spinning, 
the PBS/plasma was aspirated and the middle thin mononuclear cell layer was carefully 
removed and placed on the labeled conical tubes using 10 ml pipette, taking care to avoid 
aspiration of red blood cells. If there were some red blood cell contamination, a few 
drops of water were added to the PBMCs and allowed to stand for a few minutes to kill 
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blood cells. The cells were then washed twice with PBS and spun at 1,700 rpm for 10 
minutes. The pellets were resuspended in 20 ml of R10 media (RPMI 1640 supplemented 
with 10% heat-inactivated FCs, 100U/ml penicillin, 1,7mM sodium glutamate, 5.5 ml 
HEPES buffer). PBMC were counted using Guava Cell Counter, the cells were made up 
to 1 million per ml concentration and were then ready to be used. If the cells were going 
to be used the following day, they were kept in T25 flask and maintained in the incubator 
at 5%CO2; 37 oC. Cells not for immediate use were frozen and were stored in liquid 
nitrogen until further use. 
 
2.2.2. HLA TYPING 
 
DNA for HLA typing was extracted using Puregene DNA isolation kit for blood (Gentra 
Systems, Minneapolis, Minn.) according to the manufacturer’s instructions.  HLA Class I 
typing was done by DNA PCR using sequence specific primers as previously described 
(Kiepiela et al., 2004, Ngumbela et al., 2008). 
 
 2.2.3. VIRAL LOADS AND CD4 T CELL COUNTS 
 
Viral loads (VL) were determined from plasma using Roche Amplicor (version 1.5) and 
CD4+  T cell counts were enumerated from fresh blood by Tru-Count technology using a 
four-color FacsCalibur flow cytometer (Becton Dickinson) as previously described 






2.2.4. SYNTHETIC HIV-1 PEPTIDES 
 
A panel of 410 overlapping peptides (18 amino acids long  with  10-amino acid overlap) 
spanning the entire HIV-1 clade C consensus sequence were synthesized on an automated 
peptide synthesizer (MBS 396, Advanced ChemTech) and used in a matrix system in 
screening assays (Kiepiela et al., 2004, Goulder et al., 2001a).   Ex vivo measurement of 
T cells for IFN-γ production was undertaken by ELISPOT assay as previously reported 
(Kiepiela et al., 2004, Ngumbela et al., 2008, Thobakgale et al., 2009). The antigen-
specific T cell responses were considered positive if they were > 100 SFC above the 
unstimulated negative control wells. 
 
2.2.5. ENZYME-LINKED IMMUNOSPOT ASSAY 
 
Peptide titration and fine mapping of the HLA-C restricted epitopes were performed by 
IFN-γ ELISPOT assay. Before the addition of cells, 96 well polyvinylidene difluoride 
plate (Millipore) was coated with 0.5µg/µl of anti-IFN-γ antibody and incubated at least 
overnight at 4 oC.  The plate was then washed 6x with PBS with 1% fetal calf serum 
(FCS). The protein in the FCS prevents non-specific binding of the anti-IFN-γ antibodies. 
After washing the plates, 50 µl of R10 media (RPMI 1640 supplemented with 10% heat 
inactivated FCS, 100U/ml penicillin, 1.7 mM sodium glutamate, 5.5 ml HEPES buffer) 
was added to each well of the ELISPOT plates. For peptide titration, the 2 µg/ml 
individual peptide was serial diluted from 10-4 to 10-9 Molar and 10 µl of peptide was 
added to each well and 10 µl of PHA (250 µg/ml) was added for positive wells. The cells 
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were diluted to give 50,000 cells per well and added to each well and incubated at 37 oC, 
5% CO2 overnight. On the following day, the plate was washed with PBS 6x. 
Biotinylated anti-IFN-γ Ab (0.5µl/ml) was added and the plates incubated for 90 minutes 
in the dark. The plates were washed 6x as above and incubated with streptavidin-alkaline 
phosphatase conjugate for 45 minutes. The plate was developed using BCIP and NBT 
diluted in TRIS buffer and the reaction stopped by washing with tap water when intense 
blue spots appear in the positive control wells. Spot forming cells (SFC) were counted 
using an automatic plate reader (ImmunoSpot Software); results were expressed as spot 
forming cells (SFC)/106 PBMCs. 
 
2.2.6. DETERMINATION OF FUNCTIONAL AVIDITY USING PEPTIDE 
TITRATION ASSAY 
 
This was determined by performing limiting dilution and determining the concentration 
of peptide required to induce half maximal response. In this assay, the peptide was added 
in serial dilutions ranging from 100µg/ml to 10pg/ml in an ELISPOT assay incubated 
with freshly isolated PBMCs. Standard protocol of ELISPOT assay (Fig.3) was followed 











2.2.7. DEFINING OPTIMAL PEPTIDE BY FINEMAPPING 
 
As previously described, 410 overlapping peptides, 18 amino acids in length and 
overlapping by 10 amino acids with adjacent peptide were synthesized (Honeyborne et 
al., 2006). In cases where overlapping peptides yielded a positive response, individual 
peptides (8-11 amino acids long) were designed and tested to confirm which specific 
optimal peptide elicited the response. Each peptide was diluted by means of serial 
dilution from high concentration to low concentration (10-1M to 10-6 M). The truncated 
peptide with highest functional avidity is described as the optimal peptide.  
 
2.2.8. GENERATION OF PEPTIDE-SPECIFIC T CELL LINE 
 
Peptide-specific T cell lines were generated as previously described (Honeyborne et al., 
2006, Goulder et al., 2001b). In this assay, PBMCs were incubated with 33µg/ml for 
about one hour. There were then re-suspended in R10/50 medium (RPMI 1640 (Sigma), 
10% fetal calf serum (Sigma), 10 mM HEPES buffer with IL-2 (50U). There were then  
incubated for 1 week in culture at 37oC and 5% CO2 and medium was replaced every 3-4 
days. The specificity of the T cells was tested using intracellular cytokine staining. 
Briefly, 100,000 T cells were incubated with 33 µg/ml peptide (TF10 or RM9), another 
tube with T cells  only, and in the third tube  the T cells were stimulated with non-
specific peptide. Anti-CD28 and CD49d monoclonal antibodies (BD Bioscience) were 
added in each tube and incubated at 37oC and 5% CO2 for 30-60 minutes. Following the 
incubation, brefeldin A (10 µg/ml) was added, with further 6 hours incubation at 37oC 
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and 5% CO2.  The tubes with the T cells were then taken out from the incubator and 
placed at 4oC for further staining. The cells were washed and stained with surface 
antibody, anti-CD8 (PE) and anti-CD4 (FITC) (BD Bioscience). 
 
2.2.9. B CELL TRANSFORMATION FOR HLA RESTRICTION 
 
PBMCs were separated from the fresh blood using Histopaque; the cells were counted 
using Guava Via Cell Count. The cells were spun down at 1,700 rpm for 5 minutes, the 
supernatant was discarded and the cells were added on the 24 well plates. The cells were 
mixed with 0.5 ml filtered heat inactivated FCS, 0.5 ml EBV stock, 7.5 µl CSA (of a 
20µg/ml stock) and the final concentration of cyclosporine A was 0.1 µg/ml (CSA 
inhibits T cells). The volume was made up to 1.5 ml with R20 (RPMI 1640 supplemented 
with 20% heat-inactivated FCS, 100U/ml penicillin, 1.7mM sodium glutamate, 5.5 ml 
HEPES buffer) . The mixture was added in each well of the 24 well culture plates, 
preferably using the middle well and in the outside well as sterile PBS. They plates were 
kept into the incubator for 7 days without disturbing them. The B cell lines take 3-6 
weeks to transform, they were fed twice a week using R20 (RPMI 1640 supplemented 
with 20% heat-inactivated FCS, 100U/ml penicillin, 1.7 mM sodium glutamate, 5.5 ml 
HEPES buffer) until dense yellow colonies were observed on the plate. The cells were 
then transferred into T-25 flask with 6 ml of R20 (RPMI 1640 supplemented 20% heat-





2.2.10. POLYFUNCTIONALITY ANALYSIS BY MULTICOLOR FLOW 
CYTOMETRY 
 
Ex vivo measurement of CD8+ T cells for expression of IFN-γ, IL-2, MIP-1β, TNF-α and 
CD107a was assessed by multicolor flow analysis as previously described (Streeck et al., 
2008). In brief, freshly thawed cryopreserved PBMCs were resuspended to 1-2 × 106 
cells/ml in R10 media (RPMI 1640 supplemented with 10% heat-inactivated FCS,  100 
U/ml penicillin, 1.7mM sodium glutamate, 5.5 ml HEPES buffer) and rested for 2 hours 
at 37oC and 5% CO2. One million cells/ml were stimulated with optimal HLA-B*57/5801 
or HLA-Cw*-restricted peptides that represented immunodominant (≥500 SFC on 
ELISPOT) responses in the study subjects (Fig. 7A) in the presence of anti-CD28 and 
anti-CD49 co-stimulatory antibodies. A negative control with PBMCs alone and a 
positive control containing PBMCs stimulated with Staphylococcus enterotoxin B (SEB) 
were included in the assays. Anti-CD107a-PE-Cy5 (BD Biosciences) antibody was added 
and incubated for 30 minutes at 37oC, 5% CO2, followed by addition of Brefeldin A (10 
µg/ml, Sigma-Aldrich, St Louis, MO) and Monensin (2.5 µg/ml, Sigma-Aldrich) and 
incubated at 37oC, 5% CO2 for total of 6 hours. The cells were then washed with PBS 
(2% FCS), stained to differentiate between live/dead cells (violet viability dye, 
Invitrogen) and incubated for 30 minutes at 4oC. Cells were then washed and stained with 
the following surface antibodies: anti-CD3-PE Cy5.5 (Caltag), CD4-APC, CD8-APC 
Cy7 (both from BD Biosciences) and incubated for 20 min in the dark at room 
temperature. Cells were again washed and fixed in 1 % paraformaldehyde (Fix Perm A, 
Caltag) for 20 min in the dark at room temperature and were then permeabilized (Fix 
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Perm B, Caltag) and stained intracellularly with the following antibodies: anti-IFN-γ PE 
Cy7, anti-TNF-α Alexa 700, anti-MIP-1β PE, anti-IL-2 FITC (purchased from BD 
Biosciences) before incubation for 20 min in the dark at room temperature. The cells 
were washed twice with PBS and resuspended in 200 µl of PBS before acquisition on 
LSRII flow cytometer (BD Bioscience).  
 
2.2.11. SAMPLE ACQUISITION AND ANALYSIS 
 
Between 200,000 and 1,000,000 events were collected per sample. Analysis was 
performed using DIVA and FlowJo 8.3.3 software (TreeStar, Ashland, OR). Initial gating 
was on the lymphocytes population, then forward scatter height (FSC-H) versus forward 
scatter area (FSC-A) to remove doublets. Subsequently, live CD3+ T cells gating, 
followed by identification of CD8+ T cells was done; then individual gates (set based on 
the negative control), for respective functions were made to identify positive responses. 
Boolean gating was performed to create a full array of possible combination of up to 32 
response patterns. Positive responses were reported after background correction and the 
percentage of epitope-specific CD8+ T cell responses had to be at least two times higher 
than background for each tested marker. Analysis of multifunctional data was performed 
by PESTLE (version 1.6.2) and SPICE 5.0 (Mario Roederer, ImmunoTechnology 




2.3. RNA ISOLATION 
 
RNA isolation was performed using QIAamp Viral RNA isolation kit (Qiagen). Five 
hundred and sixty (560µl) of Buffer AVL which contains carrier RNA was pipette into 
1,5ml microcentrifuge tube. Plasma (140 µl) was added into the Buffer AVL-carrier 
RNA in the microcentrifuge tube and mixed by pulse-vortexing for 15 seconds. The 
mixture was incubated at room temperature (15-25oC) for 10 minutes and centrifuged 
briefly to remove droplets from the lids. Ethanol (560 µl) 96%-100% was added into the 
sample and pulse vortexed for 15 s followed by centrifugation for 1 min. The solution 
from the above step was applied to the QIAamp Mini column without wetting the rim. 
The solution was centrifuged at 6000 x g (8000 rpm) for 1 min and the column was 
placed on a new centrifuge tube after discarding the filtrate. Buffer AW1 (500µl) was 
added into QIAamp Mini column and centrifuged at 6000 x g (8000 rpm) for one min. A 
new clean 2 ml collection tube was replaced after discarding the filtrate and 500µl of 
Buffer AW2 added and centrifuged at full speed (20,000 x g; 14,000 rpm for 3 min) and 
the step repeated. A new 2 ml collection tube was placed under QIAamp Mini column 
and centrifuged for 1 min. Finally, 1.5 ml microcentrifuge tube was placed under the 
column and 60 µl of water was added to elute the RNA from the column. It was 
incubated at room temperature for 1 min and centrifuge at 6000 x g (8000 rpm) for 1 min. 




2.3.1. REVERSE TRANSCRIPTASE (RT) POLYMERASE CHAIN REACTION 
 
0.2 ml nuclease free, thin walled PCR tube was placed in ice, while master mix was being 
prepared. For each PCR tube: 14.4 µl of DEPC water was added, 20µl of 2x Reaction 
mix, 0.8 µl of 10 µM gene-specific primers (Nef and Gag) for both 5’ and 3’ outer 
primers, 0.8 µl of Superscript ™ III RT/ Platinum® Taq High Fidelity Enzyme Mix and 
5µl of RNA Template was added into the mixture. The mixture was gently mixed by 
centrifuging briefly in order to make sure that all ingredients settled at the bottom of the 
tube. The tubes were then placed in a preheated thermal cycler previously programmed 
with the following thermocycle conditions: cDNA denaturation and pre-denaturation was 
55oC for 30 min; 94oC for 2 min, PCR amplification conditions; denaturation temperature 
94oC for 15 sec, annealing temperature 55oC for 30 sec; extension step 68oC for 2 min for 
35 cycles. 
 
 The final extension temperature was 1 cycle of 68oC for 5 minutes and finally kept at 
4oC.  The second round PCR was performed using the product of the first PCR (cDNA). 
In the second round PCR, each PCR tube contains the following ingredients: 37 µl of 
DEPC water, 5 µl of 10x Taq buffer, 4 µl dNTPs, and 0.8 µl of 10 µM inner primers of 
gene-specific primers (nef and gag), 0.25 µl of Ex Taq and 3 µl of first round PCR 
product. The conditions of the second round PCR were pre-denaturation step (94oC; 2 
min), PCR amplification (94 oC; 15 sec, 56oC;15 sec, 72oC;1 min 30 sec) for 35 cycles. 
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The final extension was 1 cycle 72oC; 7 min and then a hold at 4oC until the product was 
characterized by electrophoresis on agarose gel. 
 
The amplified DNA was characterized on 1% agarose gel electrophoresis; 0.5 g of 
agarose was weighed and dissolved in 1 x TBE buffer by heating. The mixture was 
cooled down and 2.5 µl ethidium bromide was added to the mixture and mixed 
thoroughly. It was then added on the gel cast with well formers or comb allowing for a 
few minutes for it to solidify. Tank buffer (1 xTBE (Tris/Boric acid/EDTA) was added 
on the tank and the contents of each DNA tube were loaded on each well. Each well was 
loaded with molecular weight marker to determine the size of the product. The gel was 
ran for 45 min at 100 V and 400 A.  
 
2.3.2. GEL PURIFICATION 
 
PCR product was purified using QiAquick gel extraction kit. In this procedure, DNA 
fragment was removed from the agarose gel with a clean sharp scalpel. Colorless, empty 
tubes were weighed and the excised DNA fragments in the tubes were also weighed to 
determine the weight of DNA, the weight of colourless tube was subtracted from the 
weight of the colorless tube with DNA. Three volumes of Buffer QG (from the kit) were 
added to one volume of gel (100 mg~100 µl). The gels together with the buffer were 
incubated at 50oC for 10 min or until the gel slice had completely dissolved. In order to 
dissolve the gel slice, it was mixed with Buffer QG and centrifuged for every 2 to 3 min 
during incubation. After dissolving the gel slice, the color of the mixture was checked to 
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see whether it was similar to Buffer QG before dissolving the gel. One gel volume of 
isopropanol was added and mixed. The QIAquick spin column was prepared and the 
mixture was applied into the column and centrifuged for 1 min. The flow-through was 
thrown out and placed back in the collection tube. In order to remove all the traces of 
agarose 0.5ml of Buffer QG was added into the column and centrifuged for 1 min. For 
direct sequencing, 0.75 ml of Buffer PE was added into the column and allowed to stand 
for 2-3 minutes and centrifuged for 1 min. the flow through was discarded and continued 
with centrifugation for another 1 min. A new 1.5 ml microcentrifugation tube was placed 
into the QiAquick column and 50 µl of water was added to elute DNA from the column 
and let the column stand for 1 min, continue with centrifugation for the next minute. The 
purified DNA was then analyzed and characterized on agarose gel; one volume of 
loading dye was added to 5 volume of purified DNA. After analyzing the DNA from the 
gel, the DNA was quantified using low molecular weight marker and DNA concentration 
calculated for sequencing. 
 
2.3.3. SEQUENCING OF GAG AND NEF GENES 
 
HIV-1 RNA was extracted from 500µl of plasma (VL <5,000 HIV-1 RNA copies/ml) or 
140µl plasma (VL >5,000 RNA copies) using QIAmp viral RNA extraction kit (Qiagen). 
RNA was reversed transcribed using one-step RT-PCR kit (Invitrogen) and gene specific 
primers under the following conditions: reverse transcription at 55 oC for 30 min, 
followed by amplification at 94 oC for 2 min, and 35 cycles of 94 oC for 15 sec, 55 oC for 
30 sec, 68 oC for 2 min; and final extension at 68 oC for 5 min.  
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Gag PCR primers were 5’-CTAGCAGTGGCGCCCGAACA-3’ and 
5’GCAGTCTTTCATTTGGTGTCCTCC-3’. The same primers were used in the second 
round PCR reaction using the following conditions: 94 oC for 2 min, followed by 35 
cycles of 94 oC for 15 sec, 58 oC for 30 sec, 72 oC for 1:30 min, with a final extension at 
72 oC for 7 min. Nef PCR primers were 5’-TTCAGCTACCACCGATTGAGA-3’ and 5’-
TGAGGGTTGGCCACTCC-3’. The PCR conditions were similar to those for gag except 
for the second round PCR reaction, where the annealing temperature was set at 56oC for 
30 sec. Purified (Qiagen) PCR products were sequenced using Big Dye v3.1 Terminator 
sequencing kit (Applied Biosystems, Foster city, CA, USA) on a XL-3100 automatic 
DNA sequencer (Applied Biosystems). Nucleotide sequences were analyzed using 
Sequencer 4.8 software (Gene Codes Corporation, Ann Arbor, MI). Alignments of 
reference and newly generated gag and nef sequences were performed using ClustalX and 
edited by Bioedit Sequence Alignment editor.  
 
2.3.4. STATISTICAL ANALYSIS 
 
Mann-Whitney U test was used to compare the median magnitude of HLA-B versus 
HLA-Cw* responses. The same test was used to compare individual effector functions or 
polyfunctional responses between HLA-B*57/5801 and HLA-Cw responses in 
individuals.  The Spearman rank correlation test was used to correlate individual and 
polyfunctional responses with viral loads and CD4 counts. Fisher’s exact test was used to 




Chapter 3. RESULTS 
 3.1 CHARACTERIZATION AND QUANTIFICATION OF HLA-CW* 
RESTRICTED EPITOPE 
 
The Sinikithemba cohort was established at 2002 in McCord Hospital, Durban. It consists 
of 451 HIV positive patients followed up since 2002, of which the time of infection was 
not known. These patients were between 15 and 60 years, including both males and 
females. HLA-typing for these patients was previously performed using HLA-Class I 
gene-specific primers (Ngumbela et al., 2008, Kiepiela et al., 2004).  Viral loads (Roche 
Amplicor) and CD4 counts (BD Facscalibur) of these patients were also determined. 
Viral loads were performed every six months while CD4 counts were performed at every 
clinic visit. The 78 patients analyzed in this study were from the Sinikithemba cohort, 
HLA-C restricted epitopes with maximum responses at least greater than 100 spot 
forming cells (SFC) from ELISPOT assay were selected from these patients and 
quantified by ICS. Using the standard ICS assay 78 patients with HLA-Cw* restricted 
CD8+ T cells responses were determined (Fig.5). 
Cw*0701-KRQEILDLWVY (Nef) (n=30), Cw*0304-YVDRFFKTL (p24) (n=14), 
Cw*0801-TPQDLNTML (p24) (n=11), Cw*0801-GAFDLSFFL (p24) (n=6), Cw*18-
FRDYVDRFF (p24) (n=8), Cw*0801-IVTDSQYAL (RT) (n=6) were the most targeted 
HLA-Cw* restricted epitopes and few patients had response to Cw*0801-
TPGIRYQYNV (RT) (n=2), Cw*6- LTNNAKTIIVHL (gp120) (n=2) (Fig.5). Cw*0701-
KY11 had high percentage of IFN-γ+ producing  CD8+ cells when compared to other 
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HLA-Cw* restricted with the median percentage of 0.5%, followed by Cw*0304-YL9 
(0.49%) and Cw*0801-IL9 (0.35%) while Cw*06-LL12 has the lowest median of 
percentage of CD8+ IFN-γ producing cells. 
 
HLA-Cw*0701-KY11 epitope had high percentage of IFN-γ producing CD8+ T cell 
when compared to other HLA-Cw* restricted epitopes (Fig. 5). Previous studies has 
shown that HLA-Cw* restricted epitopes including Gag restricted epitopes are associated 
with high viral loads when compared with HLA-A and HLA-B while HLA-B*57 Gag-
restricted epitopes are associated with low viral loads (Kiepiela et al., 2004, Kiepiela et 
al., 2007). For HLA-Cw* restricted CD8+ T cell responses with significantly high 




















































































Figure 5. Characterization of HLA-Cw* restricted CD8+ T cell responses using intracellular 
cytokine staining (ICS). Y-axis shows the percentage of CD8+ T cells producing IFN-γ and x-axis shows 






3.2 DETERMINATION OF FUNCTIONAL AVIDITY USING PEPTIDE 
TITRATION 
 
Functional avidity or TCR avidity to HLA/peptide complex is more important as a 
determinant of the magnitude of response than the peptide affinity to HLA molecules 
(Yang et al., 2003, Lichterfeld et al., 2007). There is a relationship between the functional 
avidity and CTL antiviral activity, and this  was demonstrated by comparing CTL killing 
of cells infected with panels of epitope-variant viruses to the corresponding SD50 for 
variant epitopes, showing a sigmoid relationship between avidity and infected cell killing 
(Bennett et al., 2007). In this study, the HLA-Cw* restricted epitopes with high 
percentage of IFN-γ producing CD8+ T cells, and their functional avidities were 
performed. Peptide titration curve was generated using limiting dilution assessing the 
IFN-γ responses in ELISPOT when stimulated with low concentration.  
From previous results (Fig. 5), Cw*0701-KY11 and Cw*0304-YL9 have high percentage 
of IFN-γ producing CD8+ T cells from intracellular cytokine staining, followed by 
Cw*0801-TL9 and Cw*18-FFF9. Here the HLA-Cw* restricted epitopes were serially 
diluted with R10, standard ELISPOT assay was performed assessing the IFN-γ 
production. HLA-Cw*0701-KY11 (Nef) and Cw*0801-TL9 (Nef) were shown to have 




















































































































































Figure 6. Determination of functional avidity of four dominant HLA-Cw* restricted CD8+ T cell 
responses. A. indicates the peptide titration curve of Cw*0304-YVDRFFKTL (YL9), B. Cw*0701-
KRQEILDLWVY (KY11), C. Cw*0801-TPQDLNTML (TL9), D. Cw*18-FRDYVDRFF (FFF9). This 





3.3 IDENTIFICATION AND CHARACTERIZATION OF HIV-1 SPECIFIC HLA-
C RESTRICTED CD8+ T CELLS 
 
Many studies have proved that HIV-1 specific CD8+ T cell play a crucial role in control 
of viral replication both in acute and chronic HIV-1 infection (Koup et al., 1994, Wong et 
al., 2010). The identification of new HIV-1 specific restricted epitopes is very important 
in development of vaccine especially those associated with the control of viral 
replication. HLA-B*27 and B*57- restricted HIV-1 specific CD8+ T cell epitopes are 
strongly associated with the control of viremia, however the role of HLA-Cw* restricted 
epitopes may be underestimated due its high linkage disequilibrium with other HLAs and 
there are few known HLA-Cw* restricted epitopes (Goulder et al., 1997a, Goulder et al., 
2001a). In the present study, the characterization and identification of new HLA-Cw* 
restricted epitopes was performed as a requirement in understanding its role in HIV 
replication. 
 
In the fine mapping assay, 18 amino acids long overlapping peptides were truncated into 
shorter peptides (8 to 11 amino acids long).  Firstly, the screening of responses by 
ELISPOT assay was done for all the patients. After screening, the overlapping peptide 
was confirmed as the responses for that particular patient. Overlapping peptide number 
180 (OLP#180) and OLP# 362 were determined as positive responses from these patients 
without knowing whether these responses are restricted by HLA-C or not. Each 
overlapping peptide consist of 18 amino acids sequence as depicted below and this long 
peptide was truncated into small peptides (between 8-11 amino acids long) to ascertain 
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the exact peptide sequence that constitutes an HLA class I peptide. We then performed 
HLA restriction assays using B cell lines that express particular HLA class I in order to 
confirm  specific HLA-Cw* restriction. 
 
 The sequence of optimal peptide was KKKSVTVLDVGDAYFSV (overlapping peptide 
number 180), and the truncated peptides were TVLDVGDAYF (TF10), TVLDVGDAY 
(TY9), TVLDVGDAYFS (TS11), VLDVGDAYF (VF9) and VLDVGDAYFV (VV11). 
The other overlapping peptide that was truncated for fine mapping was 
IVQQQSNLLRAIEAQQHM (overlapping peptide number 362) and the short peptides 
were RAIEAQQHM (RM9), AIEAQQHM (AM8), RAIEAQQH (RH8), LRAIEAQQHM 
(LM 10) and RAIEAQQ (RQ7). Each of these peptides was serially diluted separately 
from low concentration to the highest concentration. PBMCs from the patients with 
immune response of these overlapping peptides (180 and 362) were stimulated with serial 
diluted peptide, using standard IFN-γ ELISPOT assay. From the titration curves, the 
results showed that the optimal peptide from overlapping peptide 180 was TF10 and 
optimal peptide from overlapping peptide 362 was RM9 (Fig 7).  
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Figure 7. Optimal definition of two novel HLA-Cw*0401 (TVLDVGDAYF) and HLA-Cw*0801 
(RAIEAQQHM) -restricted epitopes. A. Peptide titration curve showing the determination of optimal 
peptide B. Determination of the specificity of HLA-C restricted CD8+ T cell  line using intracellular 
cytokine staining and HLA restriction C) HLA restriction of Cw0801-RM9 (patient’s HLA A6802/02 
B1401/1510 Cw*0801/0801) . The specificity of T cells and the HLA restriction was only performed for 





To further prove that the peptides with high responses were optimal peptides, peptide-
specific cell lines were generated as described in Materials and methods.  The specificity 
of these optimal epitopes was determined by using standard intracellular cytokine 
staining. RM9 and TF10 epitopes have high specificity when compared to the cell line 
stimulated with other peptides (Fig. 7B). HLA restriction was performed in order to 
determine the restricting HLA of the peptide.  
 
Previously, optimal epitopes were determined by either ELISPOT or intracellular 
cytokine staining assay (Honeyborne et al., 2006, Goulder et al., 2001a).   However, the 
ELISPOT assay resulted in high background of spot forming cells (SFC); intracellular 
cytokine staining assay thus became the preferable assay for HLA restriction (Fig. 7C). In 
the HLA restriction assay, the HLA-matched B cell lines are generated from patients. The 
six mis-matching B cell lines and the lines with no HLA in common with patient’s HLA 
type were chosen. The T cell line/PBMC’s of the chosen patients were added into the 
tube with the B cell line and stimulated with optimal peptide. The standard intracellular 
cytokine staining assay was followed assessing the IFN-γ producing CD8+ T cells (Fig. 
7C). In this assay, RM9 and TF10 peptide-specific cell line were incubated with B-cell 
line matched through several of the individual HLA-A, B, C expressed by donor. The 
results confirmed that RM9 is restricted by HLA-Cw*0801, while TF10 restricted by 





3.4 MAGNITUDE AND BREADTH OF HLA-B*57/5801 AND HLA-C 
RESTRICTED RESPONSES BY THE IFN-Γ ELISPOT ASSAY 
 
In addition, 37 of 451 (8.2%) participants coexpressed HLA-B*57/5801 and HLA-
Cw*07, 51 (11.3%) expressed HLA-B*57/5801 without HLA-Cw*07 and 81 (18) 
expressed HLA-Cw*07 without HLA-B*57/5801. The median age, CD4 cell counts and 
viral load for the 37 subjects who co expressed HLA-B*57/5801 and HLA-Cw*07 was 
37 years, 490 cells/µl and 6,700 copies/ml respectively. Of these 37 individuals only the 
nine further studied here had concurrent immunodominant HLA-B*57/5801-and HLA-
























ID  Sex  Age  
 CD4 
count  Viral load   HLA type  HLA-B*57/5801   HLA-C   
      (years)  (cell/ml)   (copies/ml)     epitopes  epitopes  
SK 009  Male  32 291 47,000 A*2301/74 B*1503/5702 Cw*0202/0701  TSTLQEQIAW  (p24)  KRQEILDLWVY(Nef) 
SK 215  Female  35 202 34,800 A*6802/74 B*0702/5703 Cw*07/07  ISPRTLNAW (p24)  KRQEILDLWVY(Nef) 
SK 236  Female  37 411 9,900 A*02/3002 B*0801/5801 Cw*07/07  ISPRTLNAW (p24)  KRQEILDLWVY(Nef) 
SK 251  Female  58 271 2,530 A*02/3001 B*4201/5801 Cw*07/1701  QATQDVKNW (p24)  KRQEILDLWVY(Nef) 
SK 318  Female  27 370 3,600 A*33/74 B*0702/5703 Cw*07/07  KAFSPEVIPMF (p24)  KRQEILDLWVY(Nef) 
SK 358  Female  42 264 750,000 A*0202/2301 B*08/5701 Cw*07/07  ISPRTLNAW (p24)  KRQEILDLWVY(Nef) 
SK 364  Female  38 305 11,500 A*02/3001 B*4201/5801 Cw*07/1701  QATQDVKNW (p24)  KRQEILDLWVY(Nef) 
SK 379  Male  44 267 4,310 A*0205/0208 B*0702/5801 Cw*07/07  TSTLQEQIAW  (p24)  KRQEILDLWVY(Nef) 
SK 428  Female  45 214 272,000 A*0205/0208 B*1401/5801 Cw*07/08  TSTLQEQIAW  (p24)  KRQEILDLWVY(Nef) 
Median     38 271 11,500         
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All subjects included in this study made HIV-specific CD8+ T cell responses to known 
HLA-B*57/5801 and HLA-Cw*07 epitopes as determined by IFN-γ ELISPOT (Fig 7A, 
Table 1).  Only a few individuals within the Sinikithemba study cohort had responses 
≥500/106 SFCs for both HLA-B*57/5801 and HLA-Cw*07: these high magnitude 
responses were examined further in subsequent assays. The immunodominant HLA-
B*57/5801-restricted responses were to the following four epitopes: TSTLQEQIAW 
(TW10), ISPRTLNAW (ISW9), QATQDVKNW (QW10) and KAFSPEVIPMF (KF11). 
In contrast, only one HLA-Cw* response was targeted by the study subjects: 
KRQEILDLWVY (KY11) restricted by HLA-Cw*07 (Fig.8A and B). The overall 
magnitude of the responses targeted by HLA-Cw*07 restricted epitopes was significantly 
higher than the magnitude of HLA-B*57/5801 restricted responses (p=0.0012, Mann-














Figure 8. Measurement of HLA-B*57/5801 and HLA-Cw*07-restricted T cell responses 
(A) Hierarchy of dominant epitopes presented by the study subjects expressing HLA-B*57/5801 and HLA-C alleles (n=9). Dotted line 
indicates responses above 500 SFCs from ELISPOT assay that were further tested in subsequent multicolor assays. (B) Combined 





3.5. FUNCTIONALITY PROFILES OF HLA-B*57/5801 AND HLA-C 
RESTRICTED HIV-1 SPECIFIC   CD8+ T CELL EPITOPES 
 
Previous studies of long term non-progressors have shown that HIV-1-specific CD8+ T 
cells restricted by protective alleles such as HLA-B*57 and HLA-B*27, may be more 
polyfunctional than CD8+ T cells restricted by other HLAs (Zimmerli et al., 2005, Harari 
et al., 2007, Champagne et al., 2001). To determine the functionality of HIV-specific 
CD8+ T cells restricted by alleles with different disease outcomes (HLA-B*57/5801 and 
HLA-Cw*07); we assessed the polyfunctionality of these responses in those who 
possessed them concurrently. 
  
HIV-specific CD8+ T cells polyfunctionality was evaluated using multicolor flow 
cytometry by simultaneous measurement of five functions: IFN-γ, TNF-α, IL-2, MIP-1β, 
and CD107a as previously described in other studies (De Rosa et al., 2004, Betts et al., 
2006, Streeck et al., 2008). On single function gating, IFN-γ expression was lower on 
HLA-B*57/5801 than on HLA-Cw*07 restricted HIV-1 specific CD8+ T cell epitopes 
(p=0.06; Mann-Whitney test) (Fig. 9A), consistent with ELISPOT data. A similar trend 
was observed for the other individual functions although the magnitude of other 
responses was lower than for IFN-γ. The vast majority of both HLA-B and HLA-Cw* 






The most frequently expressed function was MIP-1β at 40% for HLA-B*57/5801 and 
30% for HLA-Cw*07, with CD107a at 30% for HLA-B*57/5801 restricted CD8+ T cells 
and 28% for HLA-Cw*; and IFN-γ at 29 % for HLA-B*57/5801 versus 30% for HLA-
Cw*.  
Monofunctional IL-2 or TNF-α producing HIV-specific CD8+ T cells were very 
infrequent in this cohort of chronically infected patients and only a small proportion of 
HIV-specific CD8+ T cells expressed TNF-α responses confirming previous studies that 
this effector function is lost early in infection (Wherry et al., 2003, Lichterfeld et al., 
2004b). 
 
To further investigate potential differences in functional profiles upon stimulation with 
both HLA-B*57/5801- and HLA-Cw*-restricted peptides on all patients, we compared 
the frequencies of the different HLA-restricted CD8+ T cells expressing different 
functions detected in these individuals. The fraction of each function was determined as a 
percentage of the total CD8+ T cell response as previously described (Streeck et al., 
2008). No significant differences were observed between HLA-B*57/5801- and HLA-
Cw*-restricted responses with regard to five (p=0.64; Mann-Whitney test), four (p=0.89), 
three (p=0.87), two (p=0.22) and one function (p=0.37) (Fig. 9B). Taken together, these 
data suggest the differences in disease outcome observed for HLA-B*57/5801 and HLA-
Cw* cannot be explained by the polyfunctionality of the HIV-specific CD8+ T cell 
responses during chronic infection. In addition, polyfunctionality of CD8+ T cell 














Figure 9. Polyfunctionality of HLA-B*57/5801 and HLA-Cw*07-restricted epitopes 
(A) Magnitude of HLA-B*57/5801 and HLA-C restricted epitope responses using multicolor staining, single CD8+ T cell function 
responses are shown after background subtraction. (B) Comparison of the contribution of individual functions between HLA-
B*57/B5801 (○) and HLA-C (●) restricted epitopes in the study subjects (n=9). The fractions of the response patterns are grouped and 
color-coded by the number of functions and summarized in pie chart form where each slice of the pie represents the fraction of the 
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3.6. RELATIONSHIP BETWEEN THE POLYFUNCTIONALITY OF HLA-
RESTRICTED HIV-1 SPECIFIC CD8+ T CELLS, CD4 COUNTS AND VIRAL 
LOADS 
 
Previous studies have suggested that HLA-B-restricted HIV-1-specific CD8+ T cells are 
more polyfunctional than HLA-A and HLA-Cw* (Harari et al., 2007, Zimmerli et al., 
2005) and that the proportion of the HIV-1-specific CD8+ T cell with the highest 
functionality inversely correlate with viral loads in non-progressive disease (Betts et al., 
2006). The proportion of HIV-1-specific CD8+ T cell responses were plotted against 
CD4 counts and viral load, for all the functions (Fig. 10A and B). Since no differences 
were noted in polyfunctionality profiles of HLA-B*57/5801 and Cw*07-restricted 
epitopes, the total percentages across different (1-5) functions were added together to 
determine whether or not there was a relationship between the polyfunctional CD8+ T 
cells, viral load and CD4 counts. There was a significant positive correlation between 3 
or more functions and CD4 counts (p=0.006; r=0.85, Spearman test) (Fig 9A). In 
contrast, there was a negative correlation between monofunctional cells and CD4 counts 
(p=0.05; r=-0.79). However, no correlation was noted between the polyfunctional or 














Figure 10. Relationship between mono-functional and poly-functional CD8+ T cell responses 

















































































































































































































3.7 SEQUENCE VARIATION WITHIN HLA-B*57/5801 AND HLA-C 
RESTRICTED EPITOPES AND ITS IMPACT ON CD8+ T CELL 
POLYFUNCTIONALITY  
Table 2  Sequence variation in CD8+T cell epitopes presented by HLA-B*57/B5801 and HLA-
Cw*07 alleles. 
Highlighted -epitopes tested in ICS 
Unhighlighted- epitopes not tested in ICS  
HLA-B*57/5801  epitopes  HLA-C epitopes  
Patient ID  ISW9  KF11  TW10  QW9  CW*7-KY11  
   ISPRTLNAW  KAFSPEVLPMF  TSTLQEQIAW  QATQDVKNW  KRQEILDLWVY  
SK009  L--------  -----------  --S-------  ---------  -----------  
SK215  L--------  -N---------  --N-------  ---------  ---D-------  
SK236  L--------  -----------  --N-------  ---------  -----------  
SK251  L--------  -G---------  --N-------  ---------  -----------  
SK318  ---------  -----------  ----------  ---------  -----------  
SK358  L--------  -----------  --N-------  ---------  -----------  
SK364  ---------  -----------  ----S-----  ---------  -----------  
SK379  ---------  -----------  ----S-----  ---------  -----------  





Sequence variation and the accumulation of mutations over course of infection are known 
to affect epitope recognition, specificity of the T-cell receptor binding and recognition by 
HLA (Nixon et al., 1988, Goulder et al., 1997b). Next, we evaluated whether the low 
magnitude of responses noted in HLA-B*57/5801 compared to high HLA-Cw*07-
restricted CD8+ T cell responses was due to the sequence variation in the CD8+ T cell 
epitopes. Gag and nef genes were sequenced in all nine patients as the epitopes studied 
here were located in these viral proteins. HLA-B*57/5801-restricted HIV-1-specific 
CD8+ T cell epitopes had more sequence variation (6/9) when compared to HLA-Cw*07-
restricted epitopes (1/9), (p=0.05; Fisher’s exact test), despite the fact that the HLA-C-
restricted response examined is in the highly variable Nef protein. The most frequent 
sequence changes were noted in the TSTLQEQIAW (TW10) and ISPRTLNAW (ISW9) 
Gag epitopes restricted by HLA-B*57/5801, and a single sequence variation was noted in 
the Nef Cw*0701-restricted epitope KRQEILDLWVY (KY11)  restricted by HLA-
Cw*07 (Table 2). These data suggest that HLA-B*57/5801-restricted epitopes have high 
sequence variation compared to HLA-Cw*07-restricted epitopes and this may in part 
account for the low magnitude of HLA-B*57/5801- compared to HLA-Cw*07-restricted 
responses.  
 
We also investigated whether or not sequence variation impacted on CD8+ T-cell 
polyfunctionality.  CD8+ T cell polyfunctionality was assessed by comparing HLA-B 
and HLA-Cw*-restricted HIV-1-specific CD8+ T cell epitopes with or without the 
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sequence variation against the percentage of the total HIV-1-specific CD8+ T cell 
response (Fig. 11). No differences were noted between epitopes with or without sequence 
variation with regard to 3 or more functions, 2 functions and monofunctional T-cells. 
However, there was a high frequency of monofunctional HIV-1-specific CD8+ T cells 
when compared to other functions e.g. monofunctional HLA-B*57/5801 epitopes with or 
without sequence variation were higher than HLA-B*57/5801 epitopes with or without 
sequence variation expressing 3 or more functions (p=0.004, p=0.10 respectively, Mann-
Whitney test).Consequently, whereas the decrease in the frequency of the HLA-
B*57/5801- restricted responses compared to HLA-Cw*07-restricted CD8+ T-cell 
responses may have been due to sequence variation, the data implies that sequence 
variation alone may not affect the polyfunctionality of HLA-B*57/5801 or HLA-Cw*07 

















Figure 11. Evaluation of the relationship between epitope sequence variation and polyfunctionality of 
HIV-specific CD8+ T cell responses.  
 
HLA- B*57/5801 and HLA-Cw*07  restricted epitope responses with and without 
sequence variation were plotted against the percentage of total HIV-1 specific CD8+ T 
cells with 3 or more functions, bi-functional and monofunctional T cell responses 




Chapter 4. DISCUSSION AND CONCLUSION 
There is clear evidence that CD8+ T cells act on the virus infected cells by executing a 
variety of diverse functions which result in the control of viral replication (Lichterfeld et 
al., 2004a, Betts et al., 2006, Zimmerli et al., 2005). However, the mechanism of how the 
CD8+ T cell can mediate this killing effect is still unclear. It is likely that phenotypic 
differences may impact in the ability of CD8+ T cells to mediate cytolysis and secrete 
suppressive factors (Migueles and Connors, 2002, Migueles et al., 2002). There was no 
association between the breadth or the magnitude of HIV-1 specific CD8+ T cells when 
quantifying responses by ELISPOT assay and intracellular cytokine staining (Addo et al., 
2003, Kiepiela et al., 2004). The ability of CTL to kill virally infected cells is dependent 
on the HLA restriction, epitope specificity and functional affinity and avidity (Yang et 
al., 2003, Kiepiela et al., 2004). 
 
Most studies have indicated that the control of HIV replication is driven by the restricting 
HLA.  HLA-B restricted epitopes are mostly associated with the control of HIV 
replication, especially HLA-B*57 and HLA-B*27 (Kiepiela et al., 2007, Altfeld et al., 
2003a). There are few studies that have investigated the role of HLA-Cw* restricted 
epitopes in the control of HIV replication, however, there are generally few epitopes 
restricted by HLA-Cw* (Makadzange et al., 2010, Adnan et al., 2006).  HLA-Cw* 
restricted epitopes were previously underestimated due to poor serological techniques and 
close linkage disequilibrium between certain HLA-B and HLA-Cw alleles, and some 
79 
 
HLA-Cw* restricted epitopes were assigned to the linked B molecules (Goulder et al., 
1997a). Most HLA-A and B restricted epitopes have been characterized and studied, 
whereas very few HLA-Cw* restricted epitopes are known at present. In this study, 
HLA-Cw* restricted epitopes were characterized and quantified using ELISPOT and ICS 
assay. Cw*07-KY11 had the highest magnitude of responses in the present study and the 
Cw*07 allele has strong linkage disequilibrium with HLA- B. As reported before the 
magnitude of responses does not correlate with the viral control (Addo et al., 2003). In 
this study, two new HLA-Cw* restricted epitopes Cw*0401-TF10 and Cw*0801-RM9 
were optimally defined using the fine-mapping method. These new epitopes may 
contribute to the study of HLA-Cw* restricted CD8+ T cell responses in association with 
(or lack of) viral control.  
 
ELISPOT and intracellular cytokine staining (ICS) assays are widely used in vaccine 
development, measuring the immune responses induced by infection or candidate vaccine 
(Betts et al., 2005). In this study, these assays were used to measure the cytokine 
production by CD8+ T cells when stimulated with either HLA-Cw*-or HLA-B- restricted 
epitopes.  The ELISPOT assay is used to determine the secretion of cytokines especially 
the IFN-γ and IL-2. In the chronic disease stage of HIV, CD8+ T cells secrete more IFN-
γ as compared to other cytokines while in controlling subjects, CD8+ T cells produce 
other cytokines particularly IL-2. Due to the fact that the study subjects were chronically 
infected, IFN-γ production was assessed, while other cytokines were assessed in a subset 
of patients in the polyfunctionality assays.  Recently, a whole genome wide association 
study found that a polymorphism in HLA-C may have an important role in viral control 
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(Fellay et al., 2007). HIV-1 Nef downregulates HLA-A and B and not HLA-Cw, and this 
is thought to reduce the recognition of HIV-infected cells by CTL. However, total HLA 
downregulation on the cell surface may result in elimination of virus infected cells by 
natural killer (NK) cells. The selective down regulation (of HLA-A and HLA-B but not 
HLA-C) results in the recognition of HLA-Cw* by inhibitory NK receptors thus sparing 
the infected cells from NK cell mediated elimination (Collins et al., 1998, Adnan et al., 
2006). However, HLA-Cw* surface expression is generally low but it is also known that 
HLA-Cw* restricted responses are generated during chronic infection.  
 
High levels of ELISPOT responses in chronic HIV infected patients reflect viral 
persistence and viral infection. The production of interferon gamma (IFN-γ) by CD8+ T 
cell does not define the mechanism of how the CD8+ T cell control the viral replication 
but more parameters may be a better correlate (Addo et al., 2003, Chung et al., 2007). 
The overall frequency of CD8+ T cell is not the sole determinant of immune-mediated 
protection in HIV infection (Betts et al., 2001, Addo et al., 2007). Quantification of the 
magnitude and the breadth of the CD8+ T cell responses cannot explain the impact of T 
cell in viral replication (Addo et al., 2003). 
 
 
HLA-Cw*07-KY11 has high functional avidity compared to other defined HLA-Cw* 
restricted epitopes. This suggests that Cw*07-KY11 (Nef) may bind strongly to the T cell 
receptor which induces strong immune responses. HIV-1 Nef selectively downregulates 
HLA-A and HLA-B but not C (Adnan et al., 2006, Cohen et al., 1999, Collins et al., 
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1998). Functional avidity simply refers to the half the maximal concentration required to 
induce the maximum responses and it is a measure of how strongly a peptide binds to the 
T cell receptor (Yang et al., 2003). CD8+ T cells are important in protective immunity in 
HIV-1 infection, however the factors that determine the effectiveness of antiviral activity 
of these cells still unknown. Antigen functional avidity and epitope specificity are 
proposed to influence the antiviral activity (Yang et al., 2003). 
 
The relationship between the high functional avidity of Cw*07-KY11and viral loads was 
not investigated in this study, this will require additional studies.   Cw*0304-YL9 (p24) 
and Cw*18-FFF9 (p24) have low functional avidity even though they are restricted in the 
Gag region which is associated with control. Other studies show that using cytokine 
secretion and tetramer decay assays, in chronic infection, CTL functional avidity is lower 
than in early infection in the presence of high viral replication (Lichterfeld et al., 2006, 
Lichterfeld et al., 2007). In contrast, high functional avidity and high magnitude of 
responses does not mean high functional antiviral activity of that specific CD8+ T cell. 
 
In addition, two HLA-Cw* restricted epitopes were optimally defined using IFN-γ 
ELISPOT titrating the truncated peptide. These were HLA-Cw*0401-TF10 and 
Cw*0801-RM9.  Cw*0401-TF10 is located in the RT region of the HIV proteome while 
Cw*0801-RM9 is located in gp120.  These new epitopes added new information in 
studies of HIV-HLA interaction- specifically furthering the study of HLA-Cw* restricted 
epitopes and correlation with viral control. Other studies has shown that HLA-Cw* 
restricted CTL are functionally and phenotypically the same with HLA-A and HLA-B 
82 
 
restricted CTL (Makadzange et al., 2010).  HIV-1 infected cells presenting HLA-C viral 
epitope are susceptible to lysis by HLA-Cw* restricted CTL. It is believed that a 
functional assay may provide information that will determine the relationship between 
the high functional avidity and the functionality of responses.  
 
A recent study has reported that antigen sensitivity determined the polyfunctionality of 
CD8+ T cells and HIV suppressive activity and a Gag-restricted cell line has high 
functional avidity compared to Env-specific cell line, but the high avidity did not 
correlate with the killing activity (Almeida et al., 2009). Therefore the high functional 
avidity does not imply that the epitope has high functional activity in killing the viral 
infected cells. Further functional assays like HIV suppression/inhibition assays may 
require to be performed to determine the functionality of this high functional avidity. 
 
Additionally, the mechanisms underlying better control of HIV-1 by certain HLA alleles 
are still not well understood.  Understanding these mechanisms could facilitate the 
rational design of an effective HIV-1 vaccine. Therefore,  the functional characteristics of 
CD8+ T cells responses restricted by either HLA-B*57/5801 or HLA-Cw*07 alleles 
within the same individuals in order to better understand the differences in disease 
outcome mediated by these two alleles was investigated. IFN-γ producing CD8+ T cell 
responses restricted by HLA-Cw*07 were significantly higher than responses mediated 
by HLA-B*57/5801, both on ELISPOT and intracellular cytokine staining (Fig. 8B and 
Fig. 8A).The targeted responses in the nine study subjects were representative of other 
HLA-B*57/5801-possesing persons in the larger cohort. However, the nine study 
83 
 
participants were in a relatively advanced stage of infection, as evidenced by the low 
median CD4+ T cell count of 288 cells/µl, and it is possible that this disease progression 
status may have influenced the magnitude of HLA-B*57/5801-restricted responses 
relative to HLA-C responses. On the other hand, the more obvious explanation of the 
high magnitude of HLA-C-restricted responses is the higher conservation of these 
epitopes compared to the escaped HLA-B*57/5801-restricted epitopes (Table 2). 
 
We hypothesized here that protective HLA-B restricted CD8+ T cells have a more 
polyfunctional profile compared to the non-protective HLA-C-restricted responses as has 
been described in some studies (De Rosa et al., 2004, Betts et al., 2006).   In contrast to 
these earlier studies, we found no significant differences in polyfunctional CD8+ T cell 
responses mediated by the two alleles within patients with both responses (Fig. 8B).  
Whereas in the other studies differences were analyzed between patients, here we studied 
responses occurring concurrently within a patient thus eliminating confounding by 
disease status, environmental and genetic factors. We observed a positive correlation 
between polyfunctionality and CD4+ T cell count, but no correlation with viral load 
suggesting that disease progression but not viral antigen load per se is associated with 
loss of CD8+ T cell polyfunctionality (Fig. 9A). We also observed an inverse correlation 
between the proportion of monofunctional CD8+ T cells and CD4+ T cell counts, which 
suggests that immune dysfunction as seen in late chronic HIV-1 infection is characterized 




It was recently observed in a longitudinal study of recent HIV-1 infection that CD8+ T 
cells directed against conserved epitopes lost their polyfunctionality whereas escaping-
epitope targeting CTLs appeared to maintain their original polyfunctional profile (Streeck 
et al., 2008).  We investigated here whether there were sequence variation differences in 
HLA-B*57/5801 versus HLA-Cw*07-restricted epitopes and whether such differences 
resulted in divergent CD8+ T-cell polyfunctionality profiles HLA-B*57/5801-restricted 
epitopes were more variable, perhaps suggesting increased immune selection pressure on 
these epitopes, however, there were no differences observed in polyfunctionality between 
these and immunodominant HLA-Cw*07 restricted CD8+ T cells.  
 
These results imply that sequence variation in targeted epitopes may have no impact on 
the level of polyfunctionality of CD8+ T cells during chronic HIV-1 infection, although 
as shown previously, sequence variation within a targeted epitope can impact on 
polyfunctionality over time (Streeck et al., 2008). 
 
 
The strength of this study is that CD8+ T cells were analyzed concurrently within study 
subjects with both responses of interest, thus eliminating across subject confounders. 
However, limitations include a small sample size and relatively advanced phase of 
infection of study subjects. It should be noted that the reason we analyzed such a small 
number of study participants is that most of the individuals who concurrently expressed 
HLA-B*57/5801 and Cw*07 in our cohort did not have high magnitude of response to 
epitopes restricted by these alleles, thus making it technically impossible to analyze these 
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responses in multicolor flow cytometry for those subjects with low magnitude responses. 
We have therefore focused on immunodominant responses (≥ 500 spot forming cells/106 
PBMCs) as explained under Materials and Methods. Further studies are needed to 
compare polyfunctionality between dominant and subdominant epitopes restricted by 
these two alleles although the technical hurdles outlined above will need to be addressed 
before these studies can be done. CD8+ T-cell antiviral function was not measured 
directly and are thus unable to conclude whether polyfunctionality had any association 
with antiviral functional capacity. 
 
 In summary, in late chronic HIV-1 infection, immunodominant HLA-B*57/5801 
restricted IFN-γ CD8+ T cell responses were of lower magnitude compared to 
immunodominant HLA-Cw*07-restricted responses in patients with both responses 
possibly due to differences in sequence variation in targeted epitopes.  No significant 
evidence of polyfunctionality differences between HLA-B*57/5801 versus HLA-C-
restricted CD8+ T cells. Polyfunctionality of CD8+ T cells correlated positively with 
CD4 T cell counts, suggesting that polyfunctionality is lost as disease progresses.  There 
was no impact of sequence variation within targeted epitopes on the polyfunctionality of 
restricted CD8+ T cells. Larger longitudinal studies are needed to better elucidate the 






Chapter 5. APPENDIX 
5.1 IMMUNODOMINANT HIV-1-SPECIFIC HLA-B- AND HLA-C-
RESTRICTED CD8+ T-CELLS DO NOT DIFFER IN POLYFUNCTIONALITY 
 
This manuscript was published in Virology 
Title of the Article: 
Immunodominant HIV-1-specific HLA-B- and HLA-C-restricted CD8+ T cells 
do not differ in polyfunctionality. 
Authors (sequence as in the articles) 
Nompumelelo Mkhwanazi, Christina F. Thobakgale , Mary van der Stok , Shabashini Reddy , 
Zenele Mncube , Fundisiwe Chonco, Bruce D. Walker, Marcus Altfeld , 
Philip J.R. Goulder , Thumbi Ndung'u  
 
Journal 
Virology, 2010 doi: 10.1016/j.virol.2010.06.002 
Please state your contribution to the article under the following heading. 
1. Formulation of the thesis 
I was actively involved in developing the hypothesis of this study 
2. Study design 
The Sinikithemba cohort was developed by Prof Philip Goulder, Bruce Walker, and 
Prof Thumbi Ndung’u. However, I was actively involved in designing this specific 
study, I put together a proposal including the literature review, specific aims and 
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